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Background: The endocannabinoid system is involved in many physiological and pathological processes. Two
receptors (cannabinoid receptor type 1 (CB1) and type 2 (CB2)) are known so far. Many unwanted psychotic side
effects of inhibitors of this system can be addressed to the interaction with CB1. While CB1 is one of the most
abundant neuroreceptors, CB2 is expressed in the brain only at very low levels. Thus, highly potent and selective
compounds for CB2 are desired. N-aryl-((hetero)aromatic)-oxadiazolyl-propionamides represent a promising class of
such selective ligands for the human CB2. Here, a library of various derivatives is studied for suitable routes for
labelling with 18F. Such 18F-labelled compounds can then be employed as CB2-selective radiotracers for molecular
imaging studies employing positron emission tomography (PET).
Results: By varying the N-arylamide substructure, we explored the binding pocket of the human CB2 receptor and
identified 9-ethyl-9H-carbazole amide as the group with optimal size. Radioligand replacement experiments
revealed that the modification of the (hetero)aromatic moiety in 3-position of the 1,2,4-oxadiazoles shows only
moderate impact on affinity to CB2 but high impact on selectivity towards CB2 with respect to CB1. Further, we
could show by autoradiography studies that the most promising compounds bind selectively on CB2 receptors in
mouse spleen tissue. Molecular docking studies based on a novel three-dimensional structural model of the human
CB2 receptor in its activated form indicate that the compounds bind with the N-arylamide substructure in the
binding pocket. 18F labelling at the (hetero)aromatic moiety at the opposite site of the compounds via
radiochemistry was carried out.
Conclusions: The synthesized CB2-selective compounds have high affinity towards CB2 and good selectivity
against CB1. The introduction of labelling groups at the (hetero)aromatic moiety shows only moderate impact on
CB2 affinity, indicating the introduction of potential labelling groups at this position as a promising approach to
develop CB2-selective ligands suitable for molecular imaging with PET. The high affinity for human CB2 and
selectivity against human CB1 of the herein presented compounds renders them as suitable candidates for
molecular imaging studies.
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The role of the endocannabinoid system in specific
CNS disorders is related to the regulation of the
temporal dynamics of neurotransmitter release by
the retrograde cannabinoid signalling network
[1]. Mediated by the G protein-coupled cannabinoid
receptors [2], the release of endogenous or the ad-
ministration of exogenous ligands affects both the
long-term synaptic plasticity as well as the short-term
regulation of synaptic transmission [1,3]. Two types
of specific cannabinoid receptors have been cloned
so far, termed cannabinoid receptor type 1 (CB1)
and type 2 (CB2) [2,4]. The existence of additional
cannabinoid-binding receptors has been suggested
[5,6]. In contrast to classical neurotransmitters, endo-
cannabinoids function as retrograde synaptic messen-
gers which are released from postsynaptic neurons,
diffuse across synapses, activate CB1 on presynaptic
axons and eventually suppress neurotransmitter re-
lease [7]. In addition, endocannabinoids and their
receptors control the decision about survival or death
of neuronal cells [8], such that the pharmacological
manipulation of this system might provide either neu-
roprotective or pro-apoptotic effects. A therapeutic
role of cannabinoids has also been suggested for
mood disorders [9], traumatic brain injury [10,11]
and tumour treatment [12,13]. The development of
CB2-selective anticancer agents is regarded to be
advantageous in light of unwanted central effects
exerted by binding of those agents to CB1 [14].
CB1 is abundantly expressed in the central nervous
system and has been thoroughly investigated on cellu-
lar [15] and functional levels [16,17] in the brain. In
contrast to this, only few and, to some extent, am-
biguous data are available regarding CB2 expression
and function in the brain. Initial reports stated that
CB2 is mainly expressed peripherally in the cells and
organs of the immune system such as the B
lymphocyte-enriched marginal zone of the spleen or
the cortex of lymph nodes [4,18]. However, more re-
cent studies have proven structural and functional
CB2 expression in primed glial (as reviewed in [5]) or
neural progenitor cells [19]. Moreover, CB2 mRNA
was detected in mouse [20] and rat cerebellum [21].
It could be shown in immunostaining studies that
CB2 protein is abundant under basal conditions in
neuronal and glial processes in the cerebellum and
hippocampus of mouse and rat [22-24]. As reviewed
recently by Atwood and Mackie [25], a growing num-
ber of reports substantiate a neuronal expression of
CB2 through immunohistochemical data. Thus, it has
been described that the activation of microglia is par-
alleled by an increase in CB2 immunoreactivity in the
injured brain [26]. For instance, significantly increasedCB2 expression levels were observed in severe Alzhei-
mer's disease [27]. This indicates that CB2 expressed
in the cerebellum might be involved in the pathogen-
esis of various neurodegenerative disorders and there-
fore might represent an interesting target for the
diagnostics and therapy of such diseases [14,28]. Con-
sequently, detailed investigation of the functional
changes of both receptor subtypes CB1 and CB2 is
needed to achieve a better understanding of the endo-
cannabinoid system and the effects of potential can-
nabinoid therapeutics in the normal and diseased
human brain [29].
Despite numerous in vitro approaches to directly
identify CB2 in the brain, a non-invasive and quantita-
tive analysis of these receptors in vivo has not been
reported to date, probably due to the lack of ligands ap-
plicable for molecular imaging approaches such as posi-
tron emission tomography (PET). Recently, in a
microPET study in a rat model, Evens et al. [30]
observed specific binding of the type 2 cannabinoid re-
ceptor PET tracer [11C]NE40. In this model, hCB2
receptors were locally overexpressed in the brain after
stereotactic injection of an adeno-associated viral vector
(AAV2/7) encoding hCB2R with a point mutation
(Asp80Asn) in the right striatum, yet the quantitative
analysis of these receptors in native brain tissue remains
a challenge.
Although CB2 has been already mentioned as a valu-
able biomarker of, e.g. neuroinflammation [30], the
quantitative imaging of this target requires PET radioli-
gands with superior affinity and specificity towards the
low-abundance cerebral CB2 [31]. The [11C]-methoxy-
labelled potent inverse CB2 agonist Sch225336 [32]
showed only poor brain uptake in mice under baseline
conditions. Various 18F-fluoroethoxy- [33] and [11C]-
methoxy-labelled [34] 2-oxoquinoline derivatives were
suggested as CB2 PET radioligands too, yet unfavour-
able brain-to-plasma ratios reflect the need for further
improvement(s) regarding CB2 imaging in the healthy
brain as recently reviewed [35].Methods
Here, we extend the synthesis of various CB2-binding
[36] N-aryl-((hetero)aromatic)-oxadiazolyl-propionamides
as potential PET imaging compounds. Guided by molecu-
lar docking studies employing a novel comparative model
of the human CB2 receptor, the promising site for
18F labelling was selected. In vitro binding experiments
using human CB2-transfected Chinese hamster ovary
(CHO) cells were performed. The obtained affinity data
are in good agreement with predicted binding strength
and could be verified by autoradiographic studies on
mouse spleen slices.




The substituted 1,2,4-oxadiazolyl-propionamides synthe-
sized in this study are compiled in Scheme 1.
As depicted in Scheme 2, the two-step synthesis
starts from a properly substituted nitrile and hydro-
xylamine yielding the hydroxy-amidin derivative. Fol-
lowing the route described by Cheng at al. [36], the
products were dried after dilution with methylene
chloride, and succinic acid anhydride was added to
give the 3-phenyl-subsituted 1,2,4-oxadiazole acids.
To support the formation of the oxadiazole acids,
0.1 eq. KF was added except for the compound with
R1 = Br and R2 = F. In this case, the free 3-phenyl-
substituted 1,2,4-oxadiazol-5-yl propanoic acid was
protected, employing (diazomethyl)trimethylsilane.
Subsequently, Br was substituted with CN by
addition of 4.2 eq. KCN. Deprotection with LiOH
yielded then the product. In a final step, the so
obtained differently substituted 3-((hetero)aromatic)-
1,2,4-oxadiazol-5-yl-propanoic acids were coupled to
various arylamides using standard (dimethylamino)-
pyridine (DMAP)-catalysed carbodiimide chemistry.
The obtained products were isolated either by semi-
preparative high-performance liquid chromatography
(HPLC) or crystallization (details can be found in the
‘Experimental’ section).Scheme 1 N-aryl-((hetero)aromatic)-oxadiazolyl-propionamides synthTo suggest potential radiolabelling schemes of the
compounds suitable for molecular imaging studies by
PET, several strategies were evaluated, which are given
in Scheme 3. For instance, 5e was synthesized by
methylation of 4e with methyl iodide. This approach
opens the way to introduce, for example, 11C or 18F by
N-alkylation into the final compound. A further ap-
proach is the use of prosthetic groups, such as the intro-
duction of fluorine-substituted alkyl chains via hydroxyl
groups. In this study, 6k was synthesized from 6j by
adding 1-fluoro-2-iodoethane. 18F can then be intro-
duced into the molecule by using 18F-labelled al-
kylating agents. Another approach for the synthesis of
18F-labelled compounds is the replacement of fluorine
with 18F via [2.2.2]cryptand chemistry, which is shown
in this study as an example in the ‘Radiochemistry’
section.
Figure 1 shows the single-crystal X-ray structure of
compound 6f. As expected, the amide bond of this mol-
ecule (C5-N3 in Figure 1) is in trans configuration.
Though several bonds in 6f are freely rotatable, the
structure is planar. Thus, the dihedrals of the planes
defined by the ring systems are 8.16(9)° between rings A
and B and 11.2(1)° between rings B and C.
In vitro binding studies
The specific binding of [3H]CP55,940 towards cell mem-






























1.1 eq. EDAC, 1.1 eq. aryl-amine, DCM, 1h, 0˚C and 1h, rt
washed with H2O, evaporate to dryness
1.0 eq. Benzonitrile, 24 h, 80˚C (diffuse light) DCM,
1.0 eq. Hydroxylamine, 0.5 eq. Na2CO3, MeOH/H2O = 4/1, 10 min, rt1
2
0.1 eq. KF, 3.0 eq. Succinic acid anhydride, 30 min, 130˚ - 140˚C (diffuse light)
(R1 = Br, R2 = F, X= C):
0.8/0.9 eq. succinic acid anhydride, 30 min,130˚-140˚C (diffuse light)
3a
3b
DMAP (catalyst), DCM, 1h, rt




Scheme 2 Synthesis of N-aryl-((hetero)aromatic)-oxadiazolyl-propionamides.
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accounted for 40% to 50% of total binding. Non-specific
binding was related mainly to binding to the glass fibre
(data not shown). For the binding of [3H]CP55,940 towards
hCB1-CHO and hCB2-CHO cell membranes, KD values of
2.43 ± 1.89 nM (n = 3) and 1.48 ± 0.88 nM (n = 4) were
determined in competitive binding experiments, which
correspond with recently published data [37,38]. Kinetic
analysis of the binding of [3H]CP55,940 towards hCB2-
CHO cell membranes revealed the rate constants kon =
0.266 × 109 M−1 min−1 and koff = 0.196 min
−1. The accord-
ingly estimated KD value of 0.73 nM is consistent with the
data obtained by saturation assay. The inhibition constants
(Ki) for each of the human CB receptors are compiled to-
gether with reference compounds CP55,940, SR144528,
and SR141716A in Table 1. In Figure 2, the inhibition
curves of 6f and 6h on the hCB2-CHO cell homogenatesScheme 3 Two strategies to introduce fluorine into the molecule, alloobtained in the radioligand displacement experiments with
[3H]CP55,940 are given as examples.
The data on the hCB2 affinity and selectivity of the
synthesized compounds are in good agreement with the
results published by Cheng et al. [36] and are consistent
with the therein reported potencies of similar com-
pounds. For compound 6a (compound 44 in [36]), very
high potency with an EC50 value of 0.85 nM was
obtained by functional cAMP assays. Taken together
with the high affinity measured for 6a (Ki = 6.98 nM), it
is obvious that the efficacy of this compound is mainly
caused by the strength of the direct physical interaction
with CB2. Thus, the KD values can be seen as a direct
measure of the activity of the compounds under
investigation.
As the data in Table 1 show, the variation of the aryla-
mide moiety has a significant impact on the affinitywing labelling with 18F.
Figure 1 X-ray crystal structure of 6f (50% thermal ellipsoids).
The planar ring systems have been noted by A, B and C and are
highlighted in grey.
Figure 2 Radioligand displacement study of 6f and 6h against
[3H]CP55,940 on membrane homogenates of hCB2-CHO cells.
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with carbazolamides (Y4 in Scheme 1) show, on average,
the highest affinity to hCB2. The 5-tert-butyl-isoxazol-3-
yl derivative 1a shows high affinity too, while a quinoline
substitution (Y2 in Scheme 1) results in less favourableTable 1 Affinities in nM and selectivity of the tested
compounds towards hCB1 and hCB2 expressed in CHO
cells










6b 1,560 135 1.06
6c >105 1,920
6d 7,470 12.5 2.78
6e >105 4.27
6f >105 5.89








CP55,940 2.43 1.27 0.28
SR141716A 1.26 n.d.b
SR144528 n.d.b 12.0
aAs calculated by pKi (CB2) – pKi (CB1) with pKi = -log (Ki);
b., not determined.properties. The approximately 100-fold lower hCB2 af-
finity of the 3-substituted quinoline 2a is in good agree-
ment with published efficacy data, where a 6-substituted
quinoline shows an approximately 50-fold lower [36]
efficacy in comparison to 6a. The situation is completely
different for CB1. Here, replacement of the carbazole
group with a smaller moiety results in a strong loss of
affinity towards the hCB1 receptor. For compounds 2c,
2b and 2a, binding on the hCB1 receptor could not
be observed. Weak affinity towards hCB1 could be
observed for 7h, which bears a benzyl-substituted indole
at the left-hand side. Remarkably, the affinity towards
hCB2 is lost in comparison to 6h despite the identical
2,4-diflourophenyl moieties at the 3-position of the oxa-
diazole ring. While the majority of the compounds bind
to hCB2, those with an unsubstituted nitrogen in the
ring system (aryles Y1, Y2, Y4a in Scheme 1) show no
binding to hCB1 at all. In general, the affinity of all com-
pounds towards hCB1 is much lower than that towards
hCB2. This might indicate a different binding mode of
6h and 7h at hCB2.
Comparing the compounds with the highest affinity
(6g) and the best specificity for hCB2 (6e), the cause of
this seems to be encoded in the functional group at
para-position of the phenyl group. In concordance with
published data [36], a fluorine atom at this position
increases the affinity and efficacy towards hCB2. De-
pending on its electronegativity, a second substituent at
ortho-position shows a significant impact on the affinity
as shown in Figure 3. While the introduction of -Br (6e)
or -CN (6a) leads to a higher affinity, the -OCH3 (6l)
or -OCH2CH2F (6k) substituents decrease the affinity.
Interestingly, replacement of the methoxy group with a
hydroxyl moiety (6j) results in a further loss of affinity.
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For further investigation of the CB2 affinity of the test
compounds, a preliminary autoradiographic investiga-
tion of the displacement potential of reference and test
compounds on mouse spleen tissue co-incubated with
[3H]CP55,940 has been performed. Figure 4 shows rep-
resentative autoradiograms of coronal mouse spleen
sections incubated with 6 nM [3H]CP55,940 in the pres-
ence of 1 μM of test compounds 6a, 6e and 6h. For
comparison, the autoradiograms for CP55,940, the CB1-
selective antagonist SR141716A, and the CB2-selective
antagonist SR144528 are shown in Figure 4b. As visible
in Figure 4a, the distribution of [3H]CP55,940 was het-
erogeneous within the coronal spleen sections, showing
a pattern similar to that reported previously [18,39].
Accordingly, high-density (HD) and low-density (LD)
regions were assumed to reflect binding sites in the
white or the red pulp, respectively.
To estimate the displacement efficacy of the reference
and test compounds, the intensity of the radioligand
binding in the HD regions was chosen to assess total
binding of [3H]CP55,940. Specific binding of [3H]
CPCP55,940 was calculated by subtracting the intensity
of the homogenous binding of [3H]CP55,940 determined
in the presence of 1 μM CP55,940 from the total binding
values determined in the absence or presence of 1 μM
compound. Accordingly, a high degree of specific bind-
ing of [3H]CP55,940 in mouse spleen has been identified,
which accounts for approximately 90% of total [3H]
CP55,940 binding. The density of specific binding sites
of 6 nM [3H]CP55,940 in mouse spleen, estimated by
converting the photostimulated luminescence per square
millimetre values to femtomoles per milligram wetFigure 3 Influence of substitution at ring C (cf. Figure 1) on affinity to
(Ki). High pKi values represent high affinity.weight using [3H] standards, resembles, with 150 ± 25
fmol/mg wet weight, the values reported for the bin-
ding of 10 nM [3H]CP55,940 in rat spleen (59 to 108
fmol/mg wet weight) [18]. The assignment of the
[3H]CP55,940 binding sites in mouse spleen to either
CB1 or CB2 has been obtained by co-incubating the tis-
sue with [3H]CP55,940 and either the CB1-selective
SR141716A or the CB2-selective SR144,528 antagonist.
As visible in the panels of Figure 4, co-incubation with 1
μM SR144528 displaced 78% of the specific binding of 6
nM [3H]CP55,940, while nearly no displacement has
been detected in the presence of 1 μM SR141716A. In
the latter, 94% of the specific CP55,940 binding
remained. Thus, the basal binding of [3H]CP55,940 in
mouse spleen was identified to reflect mainly CB2 bind-
ing, and the experimental conditions in this autoradio-
graphic study are suitable to assess the CB2 binding
potential of the test compounds.
At 1 μM, 6a, 6e, and 6h displaced 83%, 71%, and 66%
of the specific binding of 6 nM [3H]CP55,940 respect-
ively, and these data correlate to the rank order of CB2
affinity obtained on hCB2-CHO cells (Ki = 4.27, 6.98 and
39.4 nM, respectively). However, the displacement poten-
tial of the three compounds in mouse spleen is slightly
lower than that calculated according to the Gaddum
equation, based on which a fractional occupancy of 98%,
97% and 83%, respectively, of [3H]CP55,940 binding sites
has been estimated (cf. ‘Experimental’ section). This dif-
ference between experimental and calculated data might
reflect the previously reported non-significant variances
between affinity values obtained on native tissue by
in vitro autoradiography and in radioligand displacement
studies using transfected cells [40]. Alternatively, aswards hCB2. The pKi values were calculated according to pKi = −log
Figure 4 Autoradiogram of representative coronal sections of CD-1 mouse spleen tissue. (a) Incubated with 6 nM [3H]CP55,940. HD
binding and LD binding represent the white and the red pulp, respectively (cf. text). (b) Incubation with 1 μM selective antagonists for CB2
(SR144528) and CB1 (SR141716A). (c) Compounds 6e, 6a and 6h compete at 1 μM with the binding of [3H]CP55,940 on CB2 in good agreement
with the determined binding data: 6e > 6a > 6h.
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CP55,940-labelled mouse or human CB2, species differ-
ences might also explain the slightly distinct affinity of
the studied compounds [41].
Molecular modelling
In order to gain more insight into the binding of the herein
synthesized compounds towards hCB2, we performed mo-
lecular modelling studies. As no experimentally determined
structures of cannabinoid receptors are available yet, we
created a three-dimensional (3D) structure model of this
G protein-coupled receptor (GPCR) by comparative mod-
elling. Based on the results obtained by a sequence search
with the BLAST server, the 3D structure of the human
beta1-adrenergic receptor (bAR1) [PDB:2Y00] [42] was
identified as the structure with the highest sequence simi-
larity to the hCB2 sequence. However, during the course
of this study, a GPCR structure with a bound agonist was
published [43]. In comparison to the bAR1 structure[PDB:2Y00], which is crystalized with a bound inverse
agonist, this novel structure is more opened and thus
represents a better description of a GPCR in an active
state. Thus, the X-ray structure of the human A2A adeno-
sine receptor with UK-432097 ([PDB:3QAK]) [43] was
chosen as the template for comparative modelling. The co-
crystalized ligand of this structure was kept in place during
the building process of the receptor model to ensure a
state ready to host an agonist. Figure 5 shows the con-
structed 3D model of the human CB2 with the proposed
binding pocket. In agreement with mutagenesis data com-
piled by Poso and Huffman [44], residues known to be
involved in the binding of CP55,940 are accessible in our
model.
The results of the docking of 6a, 6e and 6h are shown
in Figure 6. The pose with the lowest predicted binding
energy is shown in green. In the majority of the pre-
dicted poses, the molecules are bent and deviated signifi-
cantly from a planar structure, which was observed for
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ation of a ligand is not necessarily identical to that of
the free molecule in solution or in a packed crystal.
Moreover, due to thermal effects, several differently
populated conformations might exist. Typically, molecu-
lar docking procedures deliver multiple suggestions for
the binding geometry of a ligand in a protein-ligand
complex. Identifying the native pose out of these sugges-
tions is often challenging, especially, if no experimentally
determined reference structure is available. By taking
into account the computed binding energy, it is possible
to weight the suggested poses employing Boltzmann
statistics.
In Figure 6 this is illustrated by encoding the energy in
the visibility of the molecule according to the method
implemented in the program PostDock [45]. While for
6h only one representative pose was predicted, for 6a
and 6e, two and three lower populated binding modes
were found, respectively. This is illustrated by the blue
shades in Figure 6, which represent the less favourable
poses of these compounds. Nevertheless, in all cases, the
three compounds bind primarily with their arylamide
moiety inside the binding pocket. A detailed analysis of
the binding site revealed a hydrophobic microdomain at
the bottom of the pocket. The comparison of 6a with 5e
indicates that a substituent at the N atom of the ring
system increases the affinity towards CB2. If such a sub-
stituent is missing like in 4e, no binding at hCB2 could
be observed (data not shown). However, a replacement
with a longer or bulkier moiety reduces the bindingFigure 5 Model of the human cannabinoid receptor type 2. (a) Side vi
protein is shown with the N-terminus at the top. (b) Top view from the ex
helices are labelled to guide the reader. Only the residues forming the bind
Finder module of MOE (Chemical Computing Group Inc., Montreal, Canada
(magenta), lipophilic (green), mild polar (blue).affinity too, as it is visible from the data obtained for 7h.
As illustrated in Figure 7, the preferred binding of 7h is
with the arylamide moiety outside the binding pocket,
which, together with the determined binding data, sub-
stantiates a different binding mode of this compound.
Thus, the 9-ethyl-9H-carbazole group seems to have an
optimal size for fitting into the CB2 binding pocket.
The low nanomolar affinity of 6a (Ki = 6.98 nM), 6e
(Ki = 4.27 nM) and 6h (Ki = 39.4 nM) towards the
human CB2 and the more than 1,000-fold selectivity
over hCB1 (Ki > 1 μM) make these fluorine-substituted
analogues the currently most promising candidates for
further development of PET imaging agents within the
series investigated. A proposed labelling at p-position of
the phenyl group at the right-hand site seems to be
favourable, e.g. the replacement of fluorine by 18F would
allow applying these compounds for molecular imaging
of CB2 receptors.Radiochemistry
The labelling with 18F was performed exemplarily on 6g,
yielding [18F]-6e, since 6e has been identified as highly
selective for hCB2 with a high affinity of Ki = 4.27 nM
(Scheme 4). 18F was introduced by microwave-assisted
nucleophilic substitution of the 4-NO2 moiety employing
[2.2.2]cryptand (Kryptofix®, VWR International GmbH,
Darmstadt, Germany). The electron-withdrawing effect
(−I effect) of the Br substituent in meta-position to the
leaving group -NO2 enables the nucleophilic attack.ew with the proposed transmembrane region shaded in grey. The
tracellular space. The extracellular loops and the transmembrane
ing pocket are shown. The binding pocket identified by the Site
) is shown as a surface with colour-coded features: H bonding
Figure 6 Predicted binding modes of 6e, 6a, 6h to human CB2 model after docking with GOLD. All compounds bind with their carbazole
moiety (ring A, cf. Figure 1) in the binding pocket indicated by black dots. The figure was created with the software MOE (Chemical Computing
Group Inc., Montreal, Canada) using the module PostDock [45]: The visibility of the surfaces is proportional to their binding energies based on
Boltzman statistics. The surfaces are colour-coded with respect to the rmsd difference to the ligand with the lowest binding energy (from yellow
to blue). As reference, the best-docked ligand is shown with cyan sticks.
Figure 7 Comparison of the predicted binding modes of 7h
and 6h to the human CB2 model. 6h (cyan) binds with the
carbazole moiety in the binding pocket. For 7h (orange), the
preferred binding is with ring A pointing outside of the cavity. This
figure was created using MOE (Chemical Computing Group Inc.,
Montreal, Canada).
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strong enough as the reaction delivered only poor yields
(3% radiochemical yield). An introduction of nitrogen into
the aromatic ring should facilitate the nucleophilic substi-
tution. Thus, the pyridine equivalent 6c was labelled with
18F under comparable conditions (Scheme 4). Though not
supported by a further electron-withdrawing substituent,
the radiochemical yield is significantly higher with 28%.
Unfortunately, compounds with a pyridine moiety as ring
C show only low affinity towards hCB2, as visible in
Table 1 (compounds 1b, 2b, 2c, 3b, 6b, 6c).
Experimental
Chemistry
All reagents were commercially obtaineda and used with-
out further purification unless otherwise stated. Anhyd-
rous solvents were transferred via an oven-dried syringe
or cannula. Flasks were oven-dried under vacuum and
cooled under a constant stream of nitrogen. 1H, 13C, and
19F nuclear magnetic resonance (NMR) spectra were
recorded on VARIAN GEMINI 2000 (200 MHz for 1H
NMR, 50 MHz for 13C NMR, 188 MHz for 19F NMR; Palo
Alto, CA, USA), VARIAN ‘MERCURY plus’ (300 MHz for
1H NMR, 75 MHz for 13C NMR, 228 MHz for 19F NMR)
and VARIAN ‘MERCURY plus’ and BRUKER DRX-400
(400 MHz for 1H NMR, 100 MHz for 13C NMR, 367
MHz for 19F NMR; Billerica, MA, USA). The chemical
shifts are reported relative to the residual solvent peak,
which was used as an internal reference (chemical shifts in
δ values, J in Hz). The following abbreviations were used
to describe peak splitting patterns when appropriate:
br = broad, s = singlet, d = doublet, t = triplet, q = quartet,
m = multiplet, dd = doublet of doublet, ddd = triplet ofdoublet, pt = pseudo-triplet. High-resolution mass spec-
trometry (MS) was performed on a Bruker Daltonics
APEX II FT-ICR, and low-resolved mass spectra (using
electrospray ionization (ESI)) were recorded on a Bruker
ESQUIRE. Reactions involving moisture-sensitive reac-
tants were performed in oven-dried glassware under an
atmosphere of nitrogen, reactants being added via a



































2 mg 1, 1.5 mL DMF
mw (pulse): (20) 65˚C, 6x30 s,
75 W, 3x60 s, 150 W, diffuse light
2 mg 1, 1.5 mL DMF
mw (pulse): (20) 80˚ -  120˚C 
75 W, 3x60 s, 75 W
Scheme 4 Radiochemistry.
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Darmstadt, Germany) and analytical thin-layer chro-
matography (TLC) on pre-coated silica gel plates
(Roth, 60 Å, F254, 0.25 mm, Carl Roth GmbH & Co.
KG, Karlsruhe, Germany). HPLC was performed on silica
gel (ReproSil-Pur 120 ODS3, C18, end-capped (endc.))
from JASCO (Jasco Labor- & Datentechnik GmbH, Groß-
Umstadt, Germany) with a HPLC from Nordantec GmbH
(Bremerhaven, Germany). All compounds were obtained
with 95% purity.
3-(3-(2-Bromo-4-fluorophenyl)-1,2,4-oxadiazol-5-yl)
propanoic acid (8) and 2-bromo-4-fluorobenzamide (9)
To a mixture of deoxygenated hydroxylamine hydro-
chloride (517 mg, 7.4 mmol, 1.0 eq.) and sodium
carbonate (394 mg, 3.7 mmol, 0.5 eq.), methanol/water
(4:1, 35 mL) was added via a cannula, and the re-
action mixture was stirred for 10 min. 2-Bromo-4-
fluorobenzonitrile (1,487 mg, 7.4 mmol, 1.0 eq.) was
added, and the reaction mixture was stirred under dif-
fuse light for 18 h at 80°C. The reaction mixture was
diluted with dichloromethane (DCM), washed with
water and evaporated to dryness after concentration of
the solvent in vacuo. To the deoxygenated crude inter-
mediate succinic acid anhydride (638 mg, 6.4 mmol, 0.9
eq.) was added, and the reaction mixture was stirred
under diffuse light for 30 min at 140°C. The crude ma-
terial was purified by column chromatography on silica
gel (eluting with petrol spirit or petrol ether/ethyl acet-
ate/acetic acid 1:1:0.01) and by crystallization at room
temperature (DCM/methanol/water) to give 8 (566 mg,
1.8 mmol, 24% yield) and 9 (559 mg, 2.6 mmol, 35%
yield). 8: 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.84
(dd, J = 6 Hz, J = 9 Hz, 1H, CH), 7.47 (dd, J = 3 Hz, J =
8 Hz, 1H, CH), 7.14 (ddd, J = 3 Hz, J = 9 Hz, 1H, CH),
3.29 (t, J = 7 Hz, 2H, CH2), 3.01 (t, J = 7 Hz, 2H, CH2).
19F NMR (376 MHz, CDCl3): δ (ppm) = −107.89 (dd, J = 8
Hz, J = 14 Hz). 13C NMR (100 MHz, CDCl3): δ (ppm) =177.7, 176.6, 167.2, 163.4 (d, J = 256 Hz), 133.3 (d, J = 9
Hz), 124.3 (d, J = 4 Hz), 122.8 (d, J = 10 Hz), 121.7 (d, J =
25 Hz), 114.9 (d, J = 22 Hz), 30.1, 21.7. High-resolution
mass spectrometry (HRMS) (ESI, negative ion) m/z: 312.9,
314.9 [M-H]−. 9: 1H NMR (400 MHz, CD3OD): δ (ppm) =
7.51 (dd, J = 6 Hz, J = 8 Hz, 1H, CH), 7.47 (dd, J = 3
Hz, J = 9 Hz, 1H, CH), 7.19 (pt, J = 2 Hz, J = 8 Hz, 1H,
CH). 19F NMR (376 MHz, CD3OD): δ (ppm) = −111.64
(dd, J = 8 Hz, J = 15 Hz). 13C NMR (101 MHz,
CD3OD): δ (ppm) = 172.4, 164.2 (d, J = 252 Hz), 136.2
(d, J = 4 Hz), 131.5 (d, J = 9 Hz), 121.5 (d, J = 25 Hz),
121.0 (d, J = 10 Hz), 115.7 (d, J = 22 Hz). HRMS (ESI,
positive ion) m/z: 217.96086 [M+H]+.
3-(3-(2-Bromo-4-nitrophenyl)-1,2,4-oxadiazol-5-yl)
propanoic acid (10) and 2-bromo-4-nitrobenzamide (11)
The propanoic acid 10 was synthesized similar to the
synthesis of 8 but with 2-bromo-4-nitrobenzonitrile as
the reacting agent. The mixture was diluted with ethyl
acetate, and potassium fluoride (2 mg, 34 μmol, 0.1 eq.)
was added during the reaction with succinic acid anhyd-
ride. The reaction mixture was stirred under diffuse light
for 30 min at 130°C. For the purification, petrol spirit or
petrol ether/ethyl acetate/acetic acid (1:1:0.005) was
used, resulting in 10 (24 mg, 70 μmol, 16% yield) and 11
(22 mg, 90 μmol, 20% yield). 10: 1H NMR (300 MHz,
CDCl3/CD3OD 1:1): δ (ppm) = 8.56 (d, J = 2 Hz, 1H,
CH), 8.29 (dd, J = 2 Hz, J = 9 Hz, 1H, CH), 7.89 (d, J = 9
Hz, 1H, CH). 13C NMR (75 MHz, CDCl3/CD3OD 1:1): δ
(ppm) = 1,178.9, 173.0, 166.0, 148.5, 133.5, 132.2, 128.5,
122.0, 121.7, 29.4, 21.3. HRMS (ESI, negative ion) m/z:
339.95731 [M-H+]−, 680.92128 [2M-H+]−. 11: 1H NMR
(300 MHz, CDCl3/CD3OD): δ (ppm) = 8.50 (d, J = 2 Hz,
1H, CH), 8.28 (dd, J = 2 Hz, J = 8 Hz, 1H, CH), 7.68
(d, J = 8 Hz, 1H, CH). 13C NMR (100 MHz, CDCl3/
CD3OD): δ (ppm) = 171.4, 150.0, 145.7, 130.6, 129.1,
123.7, 120.7. HRMS (ESI, positive ion) m/z: 244.95569
[M+H]+.
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propanoic acid (12) and 2-fluoro-4-nitrobenzamide (13)
Compounds 12 and 13 were prepared using 2-fluoro-4-
nitrobenzonitrile (prepared as in the synthesis for 10):
12: 807 mg, 2.9 mmol, 10% yield; 13: 93 mg, 0.5 mmol,
2% yield. 12: 1H NMR (300 MHz, CDCl3): δ (ppm) =
8.26 (dd, J = 7 Hz, J = 8 Hz, 1H, CH), 8.06 to 8.18 (m, 2H,
2xCH), 3.32 (t, J = 7 Hz, 2H, CH2), 3.03 (t, J = 7 Hz, 2H,
CH2).
19F NMR (282 MHz, CDCl3): δ (ppm) = −103.63
(dd, J = 7 Hz, J = 10 Hz). 13C NMR (75 MHz, CDCl3): δ
(ppm) = 178.8, 176.0, 164.1 (d, J = 6 Hz), 160.5 (d, J = 263
Hz), 150.4 (d, J = 8 Hz), 131.8 (d, J = 3 Hz), 121.4 (d, J =
13 Hz), 119.5 (d, J = 4 Hz), 112.8 (d, J = 26 Hz), 30.7,
22.5. HRMS (ESI, negative ion) m/z: 280.03753 [M-H+]−,
316.01425 [M+Cl−]−, 561.08202 [2M-H+]−. 13: 1H NMR
(400 MHz, CD3OD): δ (ppm) = 8.18 to 8.07 (m, 2H,
2xCH), 7.97 (dd, J = 7 Hz, J = 8 Hz, 2H, CH2).
19F NMR
(376 MHz, CD3OD): δ (ppm) = −112.07 (t, J = 8 Hz).
13C NMR (101 MHz, CD3OD): δ (ppm) = 166.9, 160.8
(d, J = 254 Hz), 151.5 (d, J = 9 Hz), 132.8 (d, J = 3 Hz),
130.1 (d, J = 15 Hz), 120.5 (d, J = 4 Hz), 113.1 (d, J = 29
Hz). HRMS (ESI, positive ion) m/z: 185.03583 [M+H]+,
207.01776 [M+Na]+, 391.04643 [2M+Na]+.3-(3-(2-Bromo-4-methoxyphenyl)-1,2,4-oxadiazol-5-yl)
propanoic acid (14) and 2-bromo-4-methoxybenzamide
(15)
Compounds 14 and 15 were prepared using 2-bromo-4-
methoxybenzonitrile (prepared as in the synthesis of 10):
14: 2539 mg, 7.8 mmol, 33% yield; 15: impure. 14: 1H
NMR (300 MHz, CD3OD): δ (ppm) = 7.74 (d, J = 9 Hz,
1H, CH), 7.31 (d, J = 2 Hz, 1H, CH), 7.04 (dd, J = 3 Hz,
J = 9 Hz, 1H, CH), 3.86 (s, 3H, CH3), 3.24 (t, J = 7 Hz,
2H, CH2), 2.92 (t, J = 7 Hz, 2H, CH2). Impurity: δ
(ppm) = 2.56 (s, 1.0H). 13C NMR (76 MHz, CD3OD): δ
(ppm) = 180.2, 175.1, 168.8, 163.2, 133.9, 123.6, 121.5,
120.6, 114.4, 56.3, 31.1, 22.9. Impurity: δ (ppm) = 176.2,
29.9. HRMS (ESI, negative ion) m/z: 324.98282 [M-H+]−,
650.97272 [2M-H+]−. 15: 1H NMR (300 MHz, CD3OD):
δ (ppm) = 7.44 (d, J = 9 Hz, 1H, CH), 7.19 (d, J = 3 Hz,
1H, CH), 7.00 (dd, J = 3 Hz, J = 9 Hz, 1H, CH), 3.83
(s, 3H, CH3). Impurity: δ (ppm) = 3.67 (s, 14.4H), 2.59
(s, 16H), 2.57 (s, 10H). HRMS (ESI, positive ion) m/z:
324.98282 [M-H+]−, 229.98094 [M+H]+.3-(3-(2,4-Difluorophenyl)-1,2,4-oxadiazol-5-yl)propanoic
acid (16)
Carboxylic acid 16 was prepared using 2,4-difluoroben-
zonitrile (prepared as in the synthesis for 10): 5684 mg,
22.4 mmol, 64% yield. 16: 1H NMR (300 MHz, CDCl3/
CD3OD 1:1): δ (ppm) = 8.04 (dd, J = 8 Hz, J = 16 Hz,
1H, CH), 7.14 to 6.96 (m, 2H, 2xCH), 3.24 (t, J = 7 Hz,
2H, CH2), 2.92 (t, J = 7 Hz, 2H, CH2).
19F NMR (282MHz, CDCl3/CD3OD 1:1): δ (ppm) = −104.91 to −105.25
(m, 1xF), −105.85 to −106.23 (m, 1xF). 13C NMR (75
MHz, CDCl3/CD3OD 1:1): δ (ppm) = 179.5, 174.2, 165.4
(d, J = 12 Hz, J = 254 Hz), 165.0 (d, J = 6 Hz), 161.9 (d, J =
12 Hz, J = 260 Hz), 132.8 (dd, J = 4 Hz, J = 10 Hz), 112.6
(dd, J = 4 Hz, J = 22 Hz), 112.1 (dd, J = 4 Hz, J = 13 Hz),
105.6 (pt, J = 26 Hz), 30.7, 22.5. HRMS (ESI, positive ion)
m/z: 255.05735 [M+H]+, 277.03917 [M+Na]+, 531.09038
[2M+Na]+.3-(3-(2-Cyano-4-fluorophenyl)-1,2,4-oxadiazol-5-yl)
propanoic acid (17)
Lithium hydroxide monohydrate (50 mg, 1.200 mmol,
5.0 eq.) in water (1.2 mL) was added to 24 (66 mg, 241
μmol, 1.0 eq.) in methanol (9.5 mL) and stirred for 2.5 h
at room temperature. Ethyl acetate (38 mL) and HCl
solution (13 mL, 6 mol/L) were added, and the phases
were mixed and separated. The aqueous HCl layer was
washed with ethyl acetate, and the solvent was concen-
trated in vacuo. This material was used without further
purification; 17: 58 mg, 221 μmol, 92% yield. 17: 1H
NMR (300 MHz, CDCl3, 50°C): δ (ppm) = 8.51 (s broad,
1H, COOH), 8.15 (dd, J = 5 Hz, J = 9 Hz, 1H, CH), 7.53
(dd, J = 3 Hz, J = 8 Hz, 1H, CH), 7.42 (ddd, J = 3 Hz,
J = 9 Hz, 1H, CH), 3.30 (t, J = 7 Hz, 2H, CH2), 3.01
(t, J = 7 Hz, 2H, CH2).
19F NMR (282 MHz, CDCl3,
50°C): δ (ppm) = −106.90 (dd, J = 8 Hz, J = 13 Hz). 13C
NMR (75 MHz, CDCl3, 50°C): δ (ppm) = 178.9, 175.8,
165.6, 163.3 (d, J = 256 Hz), 132.3 (d, J = 9 Hz), 125.7
(d, J = 4 Hz), 121.8 (d, J = 25 Hz), 120.6 (d, J = 22 Hz),
116.0 (m), 113.3 (d, J = 9 Hz), 52.2, 30.0, 21.9. MS (ESI,




The propanoic acid 18 was prepared using 26 (prepared
as for the synthesis of 17): 119 mg, 412 μmol, 99% yield.
18: 1H NMR (300 MHz, CDCl3): δ (ppm) = 8.74 (d, J =
2 Hz, 1H, CH), 8.58 (dd, J = 2 Hz, J = 9 Hz, 1H, CH),
8.38 (d, J = 9 Hz, 1H, CH), 3.27 (t, J = 7 Hz, hidden by
solvent, CH2), 2.93 (t, J = 7 Hz, 2H, CH2).
13C NMR (76
MHz, CDCl3): δ (ppm) = 182.1, 174.9, 166.5, 150.4,
135.4, 132.7, 131.1, 129.1, 116.8, 113.4, 30.9, 23.0. MS
(ESI, negative ion) m/z: 287 [M-H+]−, 575[2M-H+]−.
3-(3-(4-Fluoro-2-hydroxyphenyl)-1,2,4-oxadiazol-5-yl)
propanoic acid (19)
To a mixture of deoxygenated tribromoborane (7,528
mg, 30.1 mmol, 8.0 eq.) in dry DCM (130 mL), a mix-
ture of 20 (1,000 mg, 3.8 mmol, 1.0 eq.) in dry DCM
(60 mL) was added via a cannula at −70°C. The reaction
mixture was stirred for 1 h at −70°C and overnight at
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with saturated aqueous NaHCO3 solution at 1°C, washed
with ethyl acetate, and evaporated to dryness after con-
centration of the solvent in vacuo. The crude material
was purified by column chromatography on silica gel
(eluting with DCM/MeOH = 9:1 and DCM/MeOH =
1:1). Water was added and the product was additionally
purified by washing with DCM to give 19 (188 mg, 746
μmol, 20%). 19: 1H NMR (400 MHz, CD3OD): δH
(ppm) = 7.97 (pdd, J = 7 Hz, J = 9 Hz, 1H, CH), 6.79 to
6.71 (m, 2 H, 2xCH), 3.27 (t, J = 7 Hz, 2H, CH2), 2.94 (t,
J = 7 Hz, 2H, CH2).
19F NMR (376 MHz, CD3OD): δF
(ppm) = −109.06 to −109.20 (m). 13C NMR (101 MHz,
CD3OD): δC (ppm) = 180.3, 175.1, 167.5, 166.9 (d, J =
250 Hz), 160.0 (d, J = 13 Hz), 131.6 (d, J = 11 Hz), 109.3
(d, J = 3 Hz), 108.5 (d, J = 23 Hz), 105.1 (d, J = 25 Hz),
31.0, 22.9. HR ESI -MS: C11H9FN2O4, m/z = 251.04731
[M-H+]−, 503.10122 [2M-H+]−.3-(3-(4-Fluoro-2-methoxyphenyl)-1,2,4-oxadiazol-5-yl)
propanoic acid (20)
Carboxylic acid 20 was prepared using 4-fluoro-2-
methoxybenzonitrile (prepared as in the synthesis for
8): 1,250 mg, 4.7 mmol, 15% yield. 20: 1H NMR (400
MHz, CD3OD): δ (ppm) = 7.99 (dd, J = 7 Hz, J = 9 Hz,
1H, CH), 6.97 (dd, J = 2 Hz, J = 11 Hz, 1H, CH), 6.82
(ddd, J = 2 Hz, J = 8 Hz, J = 11 Hz, 1H, CH), 3.93
(s, 3H, CH3), 3.21 (t, J = 7 Hz, 2H, CH2), 2.82 (t, J = 7
Hz, 2H, CH2). Impurity: δ (ppm) = 3.16 (q, J = 7 Hz,
6.5H), 2.96 (s, 4.6H), 1.28 (t, J = 7 Hz, 10.2H). 19F NMR
(376 MHz, CD3OD): δ (ppm) = −108.48 (td, J = 7 Hz,
J = 11 Hz, J = 15 Hz). 13C NMR (101 MHz, CD3OD): δ
(ppm) = 180.3, 177.0 (broad), 167.1, 166.9 (d, J = 250
Hz), 161.3 (d, J = 11 Hz), 133.8 (d, J = 11 Hz), 113.2
(d, J = 3 Hz), 108.3 (d, J = 22 Hz), 101.1 (d, J = 27 Hz),
56.7, 33.4 (broad), 22.1 (broad). Impurity: δ (ppm) =
177.6 (broad), 47.5, 23.8, 9.1. HRMS (ESI, negative ion)
m/z: 265.06292 [M-H+]−, 531.13261 [2M-H+]−.3-(3-(6-Bromopyridin-3-yl)-1,2,4-oxadiazol-5-yl)propanoic
acid (21)
Compound 21 was prepared using 6-bromonicotinonitrile
(prepared as in the synthesis for 8): 164 mg, 550 μmol,
10% yield. 21: 1H NMR (300 MHz, CDCl3/CD3OD 1:1,
30°C): δ (ppm) = 8.95 (dd, J = 1 Hz, J = 2 Hz, CH), 8.22
(dd, J = 2 Hz, J = 8 Hz, 1H, CH), 7.68 (dd, J = 1 Hz, J =
8 Hz, 1H, CH), 3.24 (t, J = 7 Hz, 2H, CH2), 2.92 (t, J = 7
Hz, 2H, CH2).
13C NMR (76 MHz, CDCl3/CD3OD 1:1,
30°C): δ (ppm) = 180.6, 174.1, 166.1, 149.2, 145.0, 137.9,
129.3, 123.3, 30.6, 22.5. HRMS (ESI, positive ion) m/z:
297.98160 [M+H]+, 319.96382 [M+Na]+, 616.93871
[2M+Na]+.3-(3-(6-Fluoropyridin-3-yl)-1,2,4-oxadiazol-5-yl)propanoic
acid (22)
Compound 22 was prepared using 6-fluoronicotinonitrile
(prepared as in synthesis for 10): 197 mg, 830 μmol, 5%
yield. 22: 1H NMR (400 MHz, CDCl3/CD3OD 1:1): δ
(ppm) = 8.87 to 8.83 (m, 1 H, CH), 8.48 (ddd, J = 2 Hz, J =
7 Hz, J = 8 Hz, 1H, CH), 7.15 (ddd, J = 0.4 Hz, J = 3 Hz,
J = 9 Hz, 1H, CH), 3.24 (t, J = 7 Hz, 2H, CH2), 2.93 (t, J =
7 Hz, 2H, CH2).
19F NMR (376 MHz, CDCl3/CD3OD 1:1):
δ (ppm) = −65.88 (d, J = 6 Hz). 13C NMR (101 MHz,
CDCl3/CD3OD 1:1): δ (ppm) = 180.5, 174.2, 166.0, 165.6
(d, J = 244 Hz), 147.4 (d, J = 15 Hz), 141.2 (d, J = 9 Hz),
122.2 (d, J = 5 Hz), 110.9 (d, J = 37 Hz), 30.6, 22.5. HRMS




(Diazomethyl)trimethylsilane (2 M in hexane, 1.3 mL,
2.6 mmol, 1.5 eq.) was added dropwise to deoxygenated
8 (547 mg, 1.7 mmol, 1.0 eq.) in dry toluene/methanol
(9:1, 20 mL) at 0°C, and the reaction mixture was stirred
for 30 min at room temperature. The crude product was
purified by column chromatography on silica gel (eluting
with petrol spirit or petrol ether/ethyl acetate 2:1) after
concentration of the solvent in vacuo to give 23 (560
mg, 1.7 mmol, 98% yield). 23: 1H NMR (400 MHz,
CDCl3): δ (ppm) = 7.84 (dd, J = 6 Hz, J = 9 Hz, 1H,
CH), 7.47 (dd, J = 3 Hz, J = 8 Hz, 1H, CH), 7.14 (ddd,
J = 3 Hz, J = 9 Hz, 1H, CH), 3.73 (s, 3H, CH3), 3.29
(t, J = 7 Hz, 2H, CH2), 2.94 (t, J = 7 Hz, 2H, CH2).
19F
NMR (376 MHz, CDCl3): δ (ppm) = −108.04 (dd, J = 8
Hz, J = 14 Hz). 13C NMR (101 MHz, CDCl3): δ (ppm) =
178.0, 171.6, 167.2, 163.3 (d, J = 256 Hz), 133.3 (d, J =
9 Hz), 124.5 (d, J = 4 Hz), 122.7 (d, J = 10 Hz), 121.6 (d,
J = 25 Hz), 114.8 (d, J = 21 Hz), 52.1, 30.2, 22.0. MS
(ESI, positive ion) m/z: 351 [M+Na]+.
Methyl 3-(3-(2-cyano-4-fluorophenyl)-1,2,4-oxadiazol-5-yl)
propanoate (24)
Copper(I) chloride (12 mg, 122 μmol, 0.4 eq.) was added
to deoxygenated 10 (100 mg, 304 μmol, 1.0 eq.) in dry
dimethylacetamide (2.2 mL). Potassium cyanide (79 mg,
1.215 mmol, 4.0 eq.) was added after 15 min, and the re-
action mixture was stirred for 14 h at 130°C. Saturated
ammonium chloride (2.2 mL), ethyl acetate (8.7 mL) and
water (7.6 mL) were added, and the phases were mixed
and separated. The aqueous layer was washed with ethyl
acetate. The crude product was purified by column
chromatography on silica gel (eluting with petrol spirit
or petrol ether/ethyl acetate 2:1) after concentration of
the solvent in vacuo to give 24 (23 mg, 83 μmol, 27%
yield). 24: 1H NMR (300 MHz, CDCl3): δ (ppm) = 8.15
(dd, J = 5 Hz, J = 9 Hz, 1H, CH), 7.53 (dd, J = 3 Hz, J =
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3.73 (s, 3H, CH3), 3.03 (t, J = 7 Hz, 2H, CH2), 2.96 (t, J =
7 Hz, 2H, CH2).
19F NMR (282 MHz, CDCl3): δ (ppm) =
−106.85 (ddd, J = 5 Hz, J = 8 Hz). 13C NMR (100 MHz,
CDCl3): δ (ppm) = 179.1, 171.6, 165.5, 163.2 (d, J = 256
Hz), 132.3 (d, J = 9 Hz), 125.6 (d, J = 4 Hz), 121.8 (d, J =
25 Hz), 120.6 (d, J = 21 Hz), 116.2 (d, J = 3 Hz), 113.0
(d, J = 10 Hz), 52.2, 30.1, 22.0. MS (ESI, positive ion)
m/z: 276 [M+H]+, 298 [M+Na]+.
Methyl 3-(3-(2-bromo-4-nitrophenyl)-1,2,4-oxadiazol-5-yl)
propanoate (25)
Compound 25 was prepared using 10 (prepared as in
the synthesis of 23): 230 mg, 646 μmol, 98% yield. 25:
1H NMR (400 MHz, CDCl3): δ (ppm) = 8.58 (d, J = 2
Hz, 1H, CH), 8.25 (dd, J = 2 Hz, J = 9 Hz, 1H, CH), 8.06
(d, J = 9 Hz, 1H, CH), 3.73 (s, 3H, CH3), 3.32 (t, J = 7
Hz, 2H, CH2), 2.96 (t, J = 7 Hz, 2H, CH2).
13C NMR
(101 MHz, CDCl3): δ (ppm) = 178.7, 171.5, 166.5, 148.9,
133.9, 132.7, 129.2, 122.7, 122.1, 52.2, 30.1, 22.0. MS
(ESI, positive ion) m/z: 378 [M+Na]+.
Methyl 3-(3-(2-cyano-4-nitrophenyl)-1,2,4-oxadiazol-5-yl)
propanoate (26)
The carboxylic acid 26 was prepared using 10 (prepared
as for the synthesis of 24): 83 mg, 275 μmol, 43% yield.
26: 1H NMR (300 MHz, CDCl3): δ (ppm) = 8.68 (d, J =
2 Hz, 1H, CH), 8.54 (dd, J = 2 Hz, J = 9 Hz, 1H, CH),
8.39 (d, J = 9 Hz, 1H, CH), 3.73 (s, 3H, CH3), 3.34 (t, J =
7 Hz, 2H, CH2), 2.98 (t, J = 7 Hz, 2H, CH2).
13C NMR
(75 MHz, CDCl3): δ (ppm) = 179.9, 171.5, 164.9, 148.7,
134.3, 131.3, 129.7, 127.4, 115.4, 112.7, 52.2, 30.0, 22.0.
MS (ESI, positive ion) m/z: 303 [M+H]+, 325 [M+Na]+.
General amide coupling method A
The coupling reaction was initiated by dropwise addi-
tion of N-ethyl-N0-(3-dimethylaminopropyl)carbodiimide
(EDAC; 50 mg, 322 μmol, 1.1 eq.) in dry DCM (2.5 mL)
to a mixture of 1.0 eq. of the deoxygenated propanoic
acid derivate and 1.1 eq. amine in dry DCM (2.5 mL) at
0°C. The reaction mixture was stirred for 1 h at 0°C fol-
lowed by stirring for 1 h at room temperature. A tip of
spatula of 4-DMAP was added at 0°C, and the reaction
mixture was stirred for 1 h at room temperature. EDAC
(1.1 eq.) in dry DCM (2.5 mL) was added at 0°C, and the
reaction mixture was again stirred for 14 h at room
temperature followed by evaporation to dryness after
concentration of the solvent in vacuo.
3-(3-(6-Bromopyridin-3-yl)-1,2,4-oxadiazol-5-yl)-N-(5-tert-
butylisoxazol-3-yl)propanamide (1a)
Compound 1a was prepared using 14 and 5-tert-butyli-
soxazol-3-amine according to method A. The crude ma-
terial was purified by column chromatography on silicagel (elution with petrol spirit/ethyl acetate 2:1) and by
HPLC (RP18, ReproSil-Pur 120 ODS3, endc., methanol/
water = 85:15) and by crystallization at room temperature
(methanol), giving 1a (19 mg, 44 μmol, 27% yield). 1a: 1H
NMR (400 MHz, CDCl3): δ (ppm) = 10.20 (s broad, 1H,
NH), 9.01 (d, J = 2 Hz, 1H, CH), 8.16 (dd, J = 2 Hz, J = 8
Hz, 1H, CH), 7.59 (d, J = 8 Hz, 1H, CH), 6.69 (s, 1H,
CH), 3.39 (t, J = 7 Hz, 2H, CH2), 3.11 (t, J = 7 Hz, 2H,
CH2), 1.31 (s, 9H, 3×CH3).
13C NMR (76 MHz, CDCl3): δ
(ppm) = 182.2, 179.5, 168.9, 165.8, 158.0, 149.1, 145.0,
137.0, 128.5, 122.5, 93.6, 33.2, 32.5, 28.7, 22.1. HRMS




Compound 1b was synthesized similar to 1a with 22
(30 mg, 127 μmol, 1.0 eq.) as carboxylic acid component.
Before evaporating, water (5.0 mL) was added, and the
reaction mixture was washed with ethyl acetate. The
crude material was purified as described for 1a, giving
1b (14 mg, 38 μmol, 30% yield). 1b: 1H NMR (300 MHz,
CD3OD): δH (ppm) = 8.85 (d, 1H, CH), 8.52 (ddd, J = 2
Hz, J = 8 Hz, J = 9 Hz, 1H, CH), 7.26 to 7.19 (m, 1H,
CH), 6.54 (s, 1H, CH), 3.34 (t, J = 7 Hz, 2H, CH2), 3.06
(t, J = 7 Hz, 2H, CH2), 1.32 (s, 9H, 3×CH3).
19F NMR
(282 MHz, CD3OD): δF (ppm) = −67.33 (d, J = 7 Hz).
HR ESI +MS: C17H18FN5O2, m/z = 360.14680 [M+H]
+,




Compound 2a was prepared following general amide
coupling method A with 17 and quinoline-3-amine. The
crude material was purified by column chromatography on
silica gel (elution with petrol spirit/ethyl acetate 1:1, ethyl
acetate and DCM/methanol 1:1) and by crystallization at
room temperature (acetonitrile), giving pure 2a (25 mg, 64
μmol, 51% yield). 2a: 1H NMR (300 MHz, CDCl3/CD3OD
= 1:1, 50°C): δH (ppm) = 8.83 (d, J = 3 Hz, 1H, CH), 8.65
(d, J = 2 Hz, 1H, CH), 8.14 (dd, J = 5 Hz, J = 9 Hz, 1H,
CH), 7.94 (pd, J = 8 Hz, 1H, CH), 7.77 (d, J = 1 Hz, J = 8
Hz, 1H, CH), 7.64 to 7.42 (m, 4H, CH), 3.41 (t, J = 7 Hz,
2H, CH2), 3.11 (t, J = 7 Hz, 2H, CH2).
19F NMR (282 MHz,
CDCl3, 50°C): δF (ppm) = −107.89 (td, J = 5 Hz, J = 8 Hz,
J = 16 Hz). APT NMR (75 MHz, CDCl3/CD3OD = 1:1,
50°C): δC (ppm) = 180.6, 171.2, 166.3, 164.1, (d, J = 255
Hz), 145.1, 144.9, 133.1, 133.0 (d, J = 9 Hz), 129.12, 129.08,
128.6, 128.3, 127.9, 127.6, 126.3 (J = 4 Hz), 125.2, 122.4 (d,
J = 26 Hz), 121.5 (d, J = 22 Hz), 116.8 (d, J = 3 Hz), 113.4
(d, J = 9 Hz), 32.9, 22.5. HR ESI +MS: C21H14FN5O2,
m/z = 388.12051 [M+H]+, 410.10243 [M+Na]+, 775.23385
[2M+H]+, 797.21557 [2M+Na]+.
Rühl et al. Organic and Medicinal Chemistry Letters 2012, 2:32 Page 14 of 22
http://www.orgmedchemlett.com/content/2/1/323-(3-(6-Fluoropyridin-3-yl)-1,2,4-oxadiazol-5-yl)-N-
(quinolin-3-yl)propanamide (2b)
The synthesis of 2b followed the procedure described
for 2a with 21 as reactant. The crude material was puri-
fied under the same conditions as 2a, resulting in 20 mg
of 2b (55 μmol, 44% yield). 2b: 1 H NMR (400 MHz,
CDCl3/CD3OD = 1:1): δH (ppm) = 8.86 to 8.79 (m, 2H,
2xCH), 8.68 (d, J = 2 Hz, 1H, CH), 8.46 (ddd, J = 2 Hz,
J = 8 Hz, J = 8 Hz, 1H, CH), 7.93 (d, J = 8 Hz, 1H, CH),
7.77 (dd, J = 2 Hz, J = 8 Hz, 1H, CH), 7.65 to 7.58 (m,
1H, CH), 7.55 to 7.48 (m, 1H, CH), 7.12 (dd, J = 3 Hz,
J = 9 Hz, 1H, CH), 3.34 (t, J = 7 Hz, 2H, CH2), 3.11
(t, J = 7 Hz, 2H, CH2).
19F NMR (376 MHz, CDCl3/
CD3OD = 1:1): δF (ppm) = −66.00 (d, J = 7 Hz).
13C
NMR (101 MHz, CDCl3/CD3OD = 1:1): δC (ppm) =
180.7, 171.3, 166.1, 165.6 (d, J = 244 Hz), 147.5 (d, J =
15 Hz), 145.0, 144.6, 141.2 (d, J = 9 Hz), 133.2, 129.19,
129.16, 128.44, 128.41, 128.1, 125.1, 122.3 (d, J = 5 Hz),
110.9 (d, J = 37 Hz), 32.9, 22.5. HR ESI +MS:
C19H14FN5O2, m/z = 364.12066 [M+H]
+, 386.10258
[M+Na]+, 727.23464 [2M+H]+, 749.21527 [2M+Na]+.
3-(3-(6-Bromopyridin-3-yl)-1,2,4-oxadiazol-5-yl)-N-
(quinolin-3-yl)propanamide (2c)
Compound 2c was synthesized by method A, by coup-
ling 21 (50 mg, 168 μmol, 1.0 eq.) to quinolin-3-amine.
Before evaporating to dryness, water (5.0 mL) was added
to the reaction mixture and subsequently washed with
ethyl acetate. The crude material was purified as
described for 2a, giving 2c (33 mg, 77 μmol, 46% yield).
2c: 1H NMR (400 MHz, CDCl3/CD3OD = 1:1): δH
(ppm) = 8.94 (dd, J = 1 Hz, J = 2 Hz, 1H, CH), 8.78 (d,
J = 2 Hz, 1H, CH), 8.70 (d, J = 2 Hz, 1H, CH), 8.18 (dd,
J = 2 Hz, J = 8 Hz, 1H, CH), 7.93 (d, J = 8 Hz, 1H, CH),
7.76 (d, J = 1 Hz, J = 8 Hz, 1H, CH), 7.63 (dd, J = 1 Hz,
J = 8 Hz, 1H, CH), 7.63 to 7.56 (m, 1H, CH), 7.53
to 7.47 (m, 1H, CH), 3.38 (t, J = 7 Hz, 2H, CH2), 3.10 (t,
J = 7 Hz, 2H, CH2).
13C NMR (101 MHz, CDCl3/
CD3OD = 1:1): δC (ppm) = 180.5, 170.8, 166.0, 149.1,
144.9, 144.7, 144.3, 137.7, 132.9, 129.1, 129.0, 128.9,
128.3, 128.2, 127.8, 124.8, 123.1, 32.6, 22.4. HR ESI +MS:
C19H14BrN5O2, m/z = 424.04075 [M+H]
+, 446.02267
[M+Na]+, 847.07404 [2M+H]+, 869.05547 [2M+Na]+.
3-(3-(6-Fluoropyridin-3-yl)-1,2,4-oxadiazol-5-yl)-N-(1-ethyl-
1H-indol-5-yl)-propanamide (3b)
Compound 3b was synthesized by coupling deoxygenated
21 (50 mg, 211 μmol, 1.0 eq.) to 1-ethyl-1H-indol-5-amine
(37 mg, 232 μmol, 1.1 eq.) via method A. The crude ma-
terial was purified by column chromatography on silica
gel (elution with petrol spirit/ethyl acetate 1:1) and by
crystallization at room temperature (DCM/petrol spirit),
giving 3b (61 mg, 162 μmol, 77% yield). 3b: 1H NMR (300
MHz, CDCl3): δH (ppm) = 8.91 (d, J = 2 Hz, 1H, CH), 8.41(dt, J = 2 Hz, J = 8 Hz, 1H, CH), 7.76 (s, 1H, CH), 7.61
(s broad, 1H, NH), 7.24 (d, J = 10 Hz, 1H, CH), 7.21 (d, J =
2 Hz, 1H, CH), 7.10 (d, J = 3 Hz, 1H, CH), 7.02 (dd, J = 3
Hz, J = 9 Hz, 1H, CH), 6.41 (d, J = 3 Hz, 1H, CH), 4.12 (q,
J = 7 Hz, 2H, CH2), 3.38 (t, J = 7 Hz, 2H, CH2), 2.97 (t, J =
7 Hz, 2H, CH2), 1.43 (t, J = 7 Hz, 3H, CH3).
19F NMR (282
MHz, CDCl3): δF (ppm) = −64.21 (d, J = 5 Hz).
13C NMR
(76 MHz, CDCl3): δC (ppm) = 179.8, 168.4, 165.6, 165.0
(d, J = 244 Hz), 147.4 (d, J = 16 Hz), 140.2 (d, J = 9 Hz),
133.5, 129.7, 128.8, 128.1, 121.5 (d, J = 5 Hz), 115.9, 113.2,
110.1 (d, J = 38 Hz), 109.5, 41.2, 33.0, 22.5, 15.6. HR
ESI +MS: C20H18FN5O2, m/z = 380.15202 [M+H]
+,




Compound 4e was prepared using 8 and 9H-carbazol-3-
amine via coupling method A. The crude product was
purified by column chromatography on silica gel (elution
with petrol spirit/ethyl acetate 1:1, ethyl acetate and
DCM/methanol 1:1) and by HPLC (RP18, ReproSil-Pur
120 ODS3, endc., methanol/water = 85:15) and by
crystallization at room temperature (chloroform), giving
60 mg of 4e (125 μmol, 64% yield). 4e: 1H NMR (300
MHz, CD3OD): δ (ppm) = 8.26 (d, J = 2 Hz, 1H, CH),
7.96 (d, J = 8 Hz, 1H, CH), 7.82 (dd, J = 6 Hz, J = 9 Hz,
1H, CH), 7.55 (dd, J = 3 Hz, J = 9 Hz, 1H, CH), 7.49 to
7.29 (m, 4H, 4×CH), 7.21 (td, J = 2 Hz, J = 8 Hz, 1H,
CH), 7.11 (t, J = 7 Hz, 1H, CH), 3.38 (t, J = 7 Hz, 2H,
CH2), 3.04 (t, J = 7 Hz, 2H, CH2).
19F NMR (282 MHz,
CD3OD): δ (ppm) = −110.02 (td, J = 6 Hz, J = 8 Hz).
13C
NMR (76 MHz, CD3OD): δ (ppm) = 180.8, 171.4, 168.5,
164.8 (d, J = 254 Hz), 142.1, 138.7, 134.6 (d, J = 9 Hz),
131.1, 126.8, 126.1 (d, J = 4 Hz), 124.3, 124.2, 123.8 (d,
J = 10 Hz), 122.4 (d, J = 25 Hz), 121.0, 120.7, 119.7,
116.0 (d, J = 22 Hz), 113.6, 111.8, 111.6, 33.4, 23.2. HR





Compound 5e was synthesized by adding iodomethane
(8 mg, 56 μmol, 1.3 eq.) in dry dimethylformamide (0.5
mL) dropwise to deoxygenated 4e (21 mg, 43 μmol, 1.0
eq.) and potassium carbonate (59 mg, 430 μmol, 10.0
eq.). The reaction mixture was stirred for 20 h at room
temperature followed by evaporation to dryness after
concentration of the solvent in vacuo. The crude prod-
uct was purified by hot filtration in methanol and by
HPLC (RP18, ReproSil-Pur 120 ODS3, endc., aceto-
nitrile/water = 85:15) with subsequent crystallization in
the fridge (methanol) to give 5e (8 mg, 17 μmol, 39%
yield). 5e: 1H NMR (300 MHz, CDCl3/CD3OD 1:1): δ
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1H, CH), 7.81 (d, J = 9 Hz, 1H, CH), 7.57 to 7.35 (m,
hidden by solvent, 4×CH), 7.33 (d, J = 9 Hz, 1H, CH),
7.20 to 7.11 (m, 2 H, 2×CH), 3.81 (s, 3H, CH3),
3.40 (t, J = 7 Hz, 2H, CH2), 3.03 (t, J = 7 Hz, 2H,
CH2).
19F NMR (282 MHz, CDCl3/CD3OD 1:1): δ
(ppm) = −108.76 (td, J = 6 Hz, J = 8 Hz). HR ESI +MS:





For the synthesis of 6a, 17 was coupled to 9-ethyl-9H-
carbazol-3-amine as described in method A. After syn-
thesis, water (5.0 mL) was added, and the reaction
mixture was washed with ethyl acetate and evaporated
to dryness after concentration of the solvent in vacuo.
The crude product was purified by column chromatog-
raphy on silica gel (elution with petrol spirit/ethyl acet-
ate (2:1) + five drops of triethylamine and DCM/
methanol (1:1) + five drops of triethylamine) and by
crystallization at room temperature (DCM/methanol),
giving pure 6a (27 mg, 60 μmol, 50% yield). 6a: 1H NMR
(300 MHz, CDCl3/CD3OD = 1:1, 50°C): δH (ppm) = 8.28
(d, J = 2 Hz, 1H, CH), 8.13 (dd, J = 5 Hz, J = 9 Hz, 1H,
CH), 7.99 (d, J = 8 Hz, 1H, CH), 7.54 (dd, J = 2 Hz, J = 8
Hz, 1H, CH), 7.52 to 7.37 (m, 3H, 3×CH), 7.35 (d, J = 8
Hz, 1H, CH), 7.31 (d, J = 9 Hz, 1H, CH), 7.13 (pt, J = 7
Hz, 1H, CH), 4.31 (q, J = 7 Hz, 2H, CH2), 3.40 (t, J = 7 Hz,
2H, CH2), 3.04 (t, J = 7 Hz, 2H, CH2), 1.36 (t, J = 7 Hz,
3H, CH3).
19F NMR (282 MHz, CDCl3/CD3OD = 1:1, 50°
C): δF (ppm) = −107.74 (ps).
13C NMR (75 MHz, CDCl3/
CD3OD = 1:1, 50°C): δC (ppm) = 179.6, 169.2, 165.1, 162.9
(d, J = 255 Hz), 140.1, 136.9, 131.9 (d, J = 9 Hz), 129.5,
125.32, 125.26 (d, J = 4 Hz), 122.5, 122.4, 121.3 (d, J = 26
Hz), 120.3 (d, J = 22 Hz), 119.9, 119.2, 118.2, 115.8, 112.4,
112.2, 108.1, 107.9, 37.0, 32.0, 21.9, 12.9. HR ESI +MS:





Compound 6b was synthesized as 6a by coupling deoxy-
genated 22 with 9-ethyl-9H-carbazol-3-amine following
method A. The crude material was purified by column
chromatography on silica gel (elution with petrol spirit/
ethyl acetate 1:1 and DCM/methanol 1:1) and by
crystallization at room temperature (DCM/methanol),
giving 6b (42 mg, 98 μmol, 47% yield). 6b: 1H NMR
(400 MHz, CDCl3/CD3OD = 1:1): δH (ppm) = 8.83 (d, J =
2 Hz, 1H, CH), 8.47 to 8.38 (m, 1H, CH), 8.28 (d, J = 2 Hz,
1H, CH), 7.98 (d, J = 8 Hz, 1H, CH), 7.47 (dd, J = 2 Hz, J =
9 Hz, 1H, CH), 7.44 to 7.33 (m, 2H, 2×CH), 7.30 (d, J = 9
Hz, 1H, CH), 7.13 (t, J = 7 Hz, 1H, CH), 7.07 (dd, J = 2Hz, J = 8 Hz, 1H, CH), 4.30 (q, J = 7 Hz, 2H, CH2), 3.36 (t,
J = 7 Hz, 2 H, CH2), 3.03 (t, J = 7 Hz, 2H, CH2), 1.34 (t,
J = 7 Hz, 3H, CH3).
19F NMR (282 MHz, CDCl3/
CD3OD = 1:1): δF (ppm) = −65.79 (d, J = 7 Hz).
13C
NMR (101 MHz, CDCl3/CD3OD = 1:1): δC (ppm) =
180.7, 170.3, 165.9, 165.5 (d, J = 244 Hz), 147.4 (d, J =
15 Hz), 141.1 (d, J = 9 Hz), 141.0, 137.8, 130.5, 126.4,
123.5, 123.3, 122.2 (d, J = 5 Hz), 120.9, 120.1, 119.2,
113.3, 110.8 (J = 37 Hz), 109.1, 109.0, 38.0, 32.8, 22.8,
14.0. HR ESI +MS: C24H20FN5O2, m/z = 452.14902
[M+Na]+, 859.32705 [2M+H]+, 881.30861 [2M+Na]+.
3-(3-(6-Bromopyridin-3-yl)-1,2,4-oxadiazol-5-yl)-N-(9-ethyl-
9H-carbazol-3-yl)propanamide (6c)
Compound 6c was prepared as described for 6b with 21
as carboxylic acid reactant. The crude material was puri-
fied as described for 6b, giving 6c (42 mg, 86 μmol, 51%
yield). 6c: 1H NMR (300 MHz, CDCl3/CD3OD = 1:1):
δH (ppm) = 8.93 (dd, J = 1 Hz, J = 2 Hz, 1H, CH), 8.28
(d, J = 2 Hz, 1H, CH), 8.16 (dd, J = 2 Hz, J = 8 Hz, 1H,
CH), 7.97 (d, J = 8 Hz, 1H, CH), 7.60 (dd, J = 1 Hz, J = 8
Hz, 1H, CH), 7.47 (dd, J = 2 Hz, J = 9 Hz, 1H, CH), 7.44
to 7.33 (m, 2H, 2×CH), 7.30 (d, J = 9 Hz, 1H, CH), 7.17
to 7.09 (m, 1H, CH), 4.30 (q, J = 7 Hz, 2H, CH2), 3.36 (t,
J = 7 Hz, 2H, CH2), 3.03 (t, J = 7 Hz, 2H, CH2), 1.35 (t,
J = 7 Hz, 3H, CH3).
13C NMR (76 MHz, CDCl3/
CD3OD = 1:1): δC (ppm) = 180.8, 170.2, 166.0, 149.1,
144.9, 141.0 137.77, 137.75, 130.5, 129.2, 126.4, 123.4,
123.3, 120.9, 120.0, 119.2, 113.3, 109.1, 109.0, 38.0,
32.8, 22.8, 14.0. HR ESI +MS: C24H20BrN5O2, m/z =




Compound 6d was synthesized as 6a using 12. The
crude product was purified by crystallization in the
fridge (DCM), resulting in 69 mg of pure compound
(145 μmol, 81% yield). 6d: 1H NMR (400 MHz, CD3CN,
70°C): δ (ppm) = 8.39 (s broad, 1H, NH), 8.34 to 8.24
(m, 2H, 2×CH), 8.18 to 8.10 (m, 2H, 2xCH), 8.07 (d, J =
8 Hz, 1H, CH), 7.57 to 7.43 (m, 4H, 4xCH), 7.20 (t, J = 7
Hz, 1H, CH), 4.41 (q, J = 7 Hz, 2H, CH2), 3.40 (t, J = 7
Hz, 2H, CH2), 3.02 (t, J = 7 Hz, 2H, CH2), 1.39 (t, J = 7
Hz, 3H, CH3).
19F NMR (376 MHz, CD3CN, 90°C): δ
(ppm) = −106.52 (s, broad). HR ESI +MS: C25H20FN5O4,
m/z = 496.13901 [M+Na]+, 969.28932 [2M+Na]+.
3-(3-(2-Bromo-4-fluorophenyl)-1,2,4-oxadiazol-5-yl)-N-(9-
ethyl-9H-carbazol-3-yl)propanamide (6e)
Compound 6e was prepared as described for 6a using 8 as
carboxylic acid. The crude product was purified by column
chromatography on silica gel (elution with DCM/methanol
100:1) and by crystallization at room temperature (DCM/
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NMR (300 MHz, CDCl3): δ (ppm) = 8.26 (d, J = 2 Hz, 1H,
CH), 8.02 (d, J = 8 Hz, 1H, CH), 7.83 (dd, J = 6 Hz, J = 9
Hz, 1H, CH), 7.69 (s broad, 1H, NH), 7.54 to 7.42 (m, 3H,
3xCH), 7.38 (d, J = 8 Hz, 1H, CH), 7.31 (d, J = 9 Hz, 1H,
CH), 7.20 (pt, J = 8 Hz, 1H, CH), 7.12 (ddd, J = 2 Hz, J = 9
Hz, 1H, CH), 4.32 (q, J = 7 Hz, 2H, CH2), 3.45 (t, J = 7 Hz,
2H, CH2), 3.02 (t, J = 7 Hz, 2H, CH2), 1.40 (t, J = 7 Hz, 3H,
CH3).
19F NMR (282 MHz, CDCl3): δ (ppm) = −107.95
(dd, J = 8 Hz, J = 14 Hz). 13C NMR (101 MHz, CDCl3): δ
(ppm) = 178.6, 168.4, 167.2, 163.3 (d, J = 255 Hz), 140.4,
137.3, 133.3 (d, J = 9 Hz), 129.2, 125.9, 124.5 (d, J = 4 Hz),
123.0, 122.8 (d, J = 10 Hz), 122.7, 121.6 (d, J = 25 Hz),
120.6, 119.5, 118.8, 114.9 (d, J = 21 Hz), 113.0, 108.6, 108.5,
37.6, 33.1, 22.4, 13.78. HR ESI +MS: C25H20BrFN4O2,
m/z = 507.08249 [M+H]+, 529.06444 [M+Na]+,
1013.15637 [2M+H]+, 1035.13966 [2M+Na]+.
3-(3-(2-Cyano-4-nitrophenyl)-1,2,4-oxadiazol-5-yl)-N-(9-
ethyl-9H-carbazol-3-yl)propanamide (6f)
Compound 6f was synthesized as 6a using 18. The
crude product was purified by column chromato- graphy
on silica gel (elution with petrol spirit/ethyl acetate (2:1) +
five drops of triethylamine and DCM/methanol (1:1) + five
drops of triethylamine) and by crystallization at room
temperature (DCM/methanol and acetonitrile), resulting in
6f (25 mg, 51 μmol, 25%). 6f: 1H NMR (300 MHz, CD3CN,
70°C): δH (ppm) = 8.71 (d, J = 2 Hz, 1H, CH), 8.54 (dd, J =
2 Hz, J = 9 Hz, 1H, CH), 8.38 (d, J = 9 Hz, 1H, CH), 8.32
(ps, 1H, CH), 8.07 (pd, J = 8 Hz, 1H, CH), 7.54 (dd, J = 2
Hz, J = 9 Hz, 1H), 7.51 to 7.43 (m, 3H, 3×CH), 7.20 (pt, J =
7 Hz, 1H, CH), 4.41 (q, J = 7 Hz, 2H, CH2), 3.43 (t, J = 7
Hz, 2H, CH2), 3.04 (t, J = 7 Hz, 2H, CH2), 1.39 (t, J = 7 Hz,




Compound 6g was prepared as 6a but with 10 as the
reactant. The crude product was purified as described
for 6e, yielding 6g (106 mg, 198 μmol, 68%). 6g: 1H
NMR (300 MHz, CDCl3, 50°C): δH (ppm) = 8.57 (d, J =
2 Hz, 1H, CH), 8.36 to 8.14 (m, 2H, 2×CH), 8.03 (pd, J =
8 Hz, 2H, 2×CH), 7.62 to 7.13 (m, hidden by solvent),
4.35 (q, J = 7 Hz, 2H, CH2), 3.49 (ps broad, 2H, CH2),
3.04 (ps broad, 2H, CH2), 1.43 (t, J = 7 Hz, 3H, CH3).
HR ESI +MS: C25H20BrN5O4, m/z = 556.05940 [M+Na]
+,
1,067.14721 [2M+H]+, 1,089.12816 [2M+Na]+.
3-(3-(2,4-Difluorophenyl)-1,2,4-oxadiazol-5-yl)-N-(9-ethyl-
9H-carbazol-3-yl)propanamide (6h)
Compound 6h was synthesized similar to the procedure
described for 6a using 16 as carboxylic acid. The crude
product was purified by column chromatography onsilica gel (elution with petrol spirit/ethyl acetate 2:1,
petrol spirit/ethyl acetate 2:1 and DCM/methanol 1:1)
and by crystallization at room temperature (DCM/
methanol 1:1), yielding 6h (39 mg, 88 μmol, 49%). 6h:
1H NMR (400 MHz, CDCl3/CD3OD = 1:1): δH (ppm) =
8.29 (d, J = 2 Hz, 1H, CH), 8.04 (pdd, J = 8 Hz, J = 16
Hz, 1H, CH), 8.00 (d, J = 8 Hz, 1H, CH), 7.49 (dd, J = 2
Hz, J = 9 Hz, 1H, CH), 7.46 to 7.36 (m, 2H, 2xCH), 7.33
(d, J = 8 Hz, 1H, CH), 7.14 (pt, J = 6 Hz, 1H, CH), 7.06
to 6.97 (m, 2H, 2xCH), 4.33 (q, J = 7 Hz, 2H, CH2), 3.38
(t, J = 7 Hz, 2H, CH2), 3.03 (t, J = 7 Hz, 2H, CH2), 1.37
(t, J = 7 Hz, 3H, CH3).
19F NMR (376 MHz, CDCl3/
CD3OD = 1:1): δF (ppm) = −105.08 (pdd, J = 7 Hz, J =
14 Hz, 1xF), −105.89 to −106.04 (m, 1×F). 13C NMR
(101 MHz, CDCl3/CD3OD = 1:1): δC (ppm) = 179.8,
170.4, 165.4 (dd, J = 12 Hz, J = 254 Hz), 165.0 (d, J = 6
Hz), 161.9 (dd, J = 12 Hz, J = 260 Hz), 141.1, 137.9,
132.7 (dd, J = 4 Hz, J = 10 Hz), 130.5, 126.4, 123.5,
123.4, 120.9, 120.2, 119.2, 113.4, 112.6 (dd, J = 4 Hz, J =
22 Hz), 112.1 (dd, J = 4 Hz, J = 13 Hz), 109.2, 109.0, 105.6
(t, J = 26 Hz), 38.0, 32.9, 22.8, 14.0. HR ESI +MS:
C25H20F2N4O2, m/z = 447.16279 [M+H]
+, 469.14455
[M+Na]+, 893.31771 [2M+H]+, 915.29946 [M+Na]+.
3-(3-(4-Amino-2-fluorophenyl)-1,2,4-oxadiazol-5-yl)-N-(9-
ethyl-9H-carbazol-3-yl)propanamide (6i)
Tin(II) chloride (40 mg, 211 μmol, 5.0 eq.) was added
to deoxygenated 6d (20 mg, 42 μmol, 1.0 eq.) in etha-
nol (1.0 mL), and the reaction mixture was stirred for
30 min at reflux. Saturated sodium carbonate solution
(2.0 mL) was added at 0°C. The precipitate was fil-
tered up, washed with water, diluted in chloroform/
methanol (1:1), filtered and evaporated to dryness
after concentration of the solvent in vacuo. The crude
material was purified by column chromatography on
silica gel (elution with chloroform/methanol 100:1)
and by crystallization in the fridge (acetonitrile) to
give 6i (12 mg, 26 μmol, 62% yield) 6i: 1H NMR (300
MHz, CD3CN, 65°C): δ (ppm) = 8.38 (s broad, 1H,
NH), 8.32 (s, 1H, CH), 8.07 (d, J = 8 Hz, 1H, CH),
7.74 (t, J = 8 Hz, 1H, CH), 7.60 to 7.36 (m, 4H,
4×CH), 7.19 (t, J = 7 Hz, 1H, CH), 6.61 to 6.41 (m,
2H, 2×CH), 4.71 (s broad, 2 H, NH2), 4.39 (q, J = 7
Hz, 2H, CH2), 3.31 (t, J = 7 Hz, 2H, CH2), 2.96 (t, J =
7 Hz, 2H, CH2), 1.38 (t, J = 7 Hz, 3H, CH3).
19 F
NMR (282 MHz, CD3CN, 65°C): δ (ppm) = −110.20
(dd, J = 9 Hz, J = 13 Hz). HRMS (ESI, positive ion)
m/z: 466.16522 [M+Na]+, 909.34029 [2M+Na]+.
3-(3-(4-Fluoro-2-hydroxyphenyl)-1,2,4-oxadiazol-5-yl)-N-(9-
ethyl-9H-carbazol-3-yl)propanamide (6j)
Compound 6j was prepared using 19 as described in the
synthesis of 6a. The crude material was purified as
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yield). 6j: 1H NMR (300 MHz, CD3CN): δ (ppm) = 8.55
(s, broad, 1H, NH), 8.35 (d, J = 1 Hz, 1H, CH), 8.06 (pd,
J = 6 Hz, 1H, CH), 8.00 (dd, J = 5 Hz, J = 7 Hz, 1H,
CH), 7.55 to 7.42 (m, 4H, 4xCH), 7.18 (td, J = 1 Hz, J =
5 Hz, 1H, CH), 6.84 to 6.74 (m, 2H, 2xCH), 4.38 (q, J =
5 Hz, 2H, CH2), 3.37 (t, J = 5 Hz, 2H, CH2), 3.02 (t, J = 5
Hz, 2H, CH2), 1.35 (t, J = 5 Hz, 3H, CH3).
19F NMR (282
MHz, CD3CN): δ (ppm) = −108.31 to −108.44 (m). HR
ESI +MS: C25H21FN4O3, m/z = 445.16724 [M+H]
+,




Potassium carbonate (14 mg, 101 μmol, 2.0 eq.) was
added to deoxygenated 6j (22 mg, 50 μmol, 1.0 eq.) in
dry dimethylformamide (0.5 mL), and the reaction mix-
ture was stirred for 5 min. To the reaction mixture, 1-
fluoro-2-iodoethane (18 mg, 101 μmol, 2.0 eq.) was
added, and the reaction mixture was stirred for 20 h at
50°C. The reaction mixture was added to ice water,
washed with ethyl acetate and evaporated to dryness
after concentration of the solvent in vacuo. The crude
material was purified by column chromatography on sil-
ica gel (elution with petrol spirit or petrol ether/ethyl
acetate 1:1) and by crystallization at room temperature
(DCM/methanol) to give 6k (11 mg, 22 μmol, 43%
yield). 6k: 1H NMR (300 MHz, CDCl3/CD3OD 1:1): δ
(ppm) = 8.52 (s, broad, 1H, NH), 8.36 (d, J = 2 Hz, 1H,
CH), 8.06 (pd, J = 8 Hz, 1H, CH), 7.94 (dd, J = 7 Hz, J =
9 Hz, 1H, CH), 7.58 to 7.39 (m, 4H, 4×CH), 7.18 (pt, J =
7 Hz, 1H, CH), 6.93 (dd, J = 2 Hz, J = 11 Hz, 1H, CH),
6.86 (dt, J = 2 Hz, J = 8 Hz, 1H, CH), 4.88 to 4.78/4.71
to 4.61 (dm, J = 48 Hz, 1 H/1H, CH2), (m, 1H, CH2),
4.47 to 4.32/4.31 to 4.22 (m, 2H, 1H/1H, 2×CH2), 3.31
(t, J = 7 Hz, 2H, CH2), 2.98 (t, J = 7 Hz, 2H, CH2), 1.35
(t, J = 7 Hz, 3H, CH3).
19F NMR (282 MHz, CDCl3/
CD3OD 1:1): δ (ppm) = −108.79 to −108.96 (m,
1F), −223.78 to −224.42 (m, 1F). HR ESI +MS:





Compound 6l was synthesized via coupling method A as
described for 6a with 20 as carboxylic acid. The crude
material was purified following the procedure for 6e,
yielding 6l (76 mg, 166 μmol, 57%). 6l: 1H NMR (400
MHz, CDCl3/CD3OD = 1:1): δH (ppm) = 8.29 (d, J = 2
Hz, 1H, CH), 8.02 to 7.91 (m, 2H, 2×CH), 7.48 (dd, J = 2
Hz, J = 8 Hz, 1H, CH), 7.43 to 7.33 (m, 2H, 2×CH), 7.30
(d, J = 9 Hz, 1H, CH), 7.13 (pt, J = 7 Hz, 1H, CH), 6.79
(dd, J = 2 Hz, J = 11 Hz, 1H, CH), 6.72 (dd, J = 2 Hz, J =8 Hz, 1H, CH), 4.29 (q, J = 7 Hz, 2 H, CH2), 3.88 (s, 3H,
CH3), 3.35 (t, J = 7 Hz, 2H, CH2), 3.01 (t, J = 7 Hz, 2H,
CH2), 1.34 (t, J = 7 Hz, 3H, CH3).
13C NMR (101 MHz,
CDCl3/CD3OD = 1:1): δC (ppm) = 178.7, 170.5, 166.6,
166.2 (d, J = 251 Hz), 160.4 (d, J = 11 Hz), 141.1 137.8,
133.3 (d, J = 11 Hz), 130.5, 126.4, 123.5, 123.4, 120.9,
120.1, 119.2, 113.4, 112.3 (d, J = 3 Hz), 109.2, 109.0,
108.0 (d, J = 22 Hz), 100.5 (d, J = 26 Hz), 56.4, 38.0,
33.0, 22.8, 14.0. HR ESI +MS: C26H23FN4O3, m/z =
459.18247 [M+H]+, 917.35797 [2M+H]+.
3-(3-(2-Bromo-4-methoxyphenyl)-1,2,4-oxadiazol-5-yl)-N-
(9-ethyl-9H-carbazol-3-yl)propanamide (6m)
Compound 6m was synthesized as 6a with 14 as car-
boxylic acid reactant. The crude material was purified by
column chromatography on silica gel (elution with
DCM/methanol 100:1 and DCM/methanol 100:2) and
by crystallization at room temperature (DCM/methanol),
yielding 6m (83 mg, 159 μmol, 54%). 6m: 1H NMR (400
MHz, CDCl3/CD3OD = 1:1): δH (ppm) = 8.29 (s, 1H,
CH), 8.00 (d, J = 8 Hz, 1H, CH), 7.72 (d, J = 8 Hz, 1H,
CH), 7.55 to 7.27 (m, hidden by solvent, 4×CH), 7.22
(d, J = 2 Hz, 1H, CH), 7.15 (t, J = 7 Hz, 1H, CH), 6.92
(dd, J = 2 Hz, J = 9 Hz, 1H, CH), 4.32 (q, J = 7 Hz, 2H,
CH2), 3.80 (s, 3H, CH3), 3.38 (t, J = 7 Hz, 2H, CH2), 3.02
(t, J = 7 Hz, 2H, CH2), 1.36 (t, J = 7 Hz, 3H, CH3).
13C
NMR (101 MHz, CDCl3/CD3OD = 1:1): δC (ppm) =
179.4, 170.4, 168.2, 162.4, 141.0, 137.8, 133.3, 130.5, 126.4,
123.4, 123.3, 123.2, 120.9, 120.7, 120.13, 120.09, 119.2,
113.9, 113.4, 109.1, 109.0, 56.0, 38.0, 32.9, 22.8, 14.0. HR
ESI +MS: C26H23BrN4O3, m/z = 519.10249 [M+H]
+,




Compound 7h was prepared by coupling of 16 with 1-
benzyl-1H-indol-3-amine hydrochloride according to
coupling method A. The crude product was purified by
column chromatography on silica gel (elution with
petrol spirit/ethyl acetate 2:1 and ethyl acetate), yielding
7h (71 mg, 155 μmol, 87%). For affinity data, the prod-
uct (20 mg) was further purified by HPLC (RP18,
ReproSil-Pur 120 ODS3, endc., acetonitrile/0.057 M
triethylammonium acetate = 65:35) and by crystallization
at room temperature (ethanol/water) to an aspic. The
aspic was dried in a speed vacuum to give 14.7 mg of
pure solid product. 7h: 1H NMR (400 MHz, CDCl3): δH
(ppm) = 8.07 to 7.98 (m, 1H, CH), 7.92 (s broad, 1H,
NH), 7.78 (s, 1H, CH), 7.51 (d, J = 8 Hz, 1H, CH), 7.36
to 7.22 (m, hidden by solvent, 4×CH), 7.19 (pt, J = 7 Hz,
1H, CH), 7.16 to 7.10 (m, 2H, 2×CH), 7.07 (pt, J = 7 Hz,
1H, CH), 7.02 to 6.92 (m, 2H, 2×CH), 5.24 (s, 2H, CH2),
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19F NMR (376 MHz, CDCl3): δF (ppm) = −104.01
to −104.26 (m, 1xF), −104.97 to −105.20 (m, 1xF). 13C
NMR (101 MHz, CDCl3): δC (ppm) = 178.8, 167.7, 164.7
(dd, J = 12 Hz, J = 254 Hz), 164.6 (d, J = 6 Hz), 161.3
(dd, J = 12 Hz, J = 260 Hz), 137.4, 134.1, 132.1 (dd, J = 4
Hz, J = 10 Hz), 128.9, 127.8, 127.0, 122.6, 121.1, 119.9,
119.3, 116.8, 114.1, 112.1 (dd, J = 4 Hz, J = 22 Hz), 111.6
(dd, J = 4 Hz, J = 13 Hz), 110.1, 105.3 (t, J = 25 Hz),
50.3, 32.6, 22.6. HR ESI +MS: C26H20F2N4O2, m/z =
481.14447 [M+Na]+, 939.29960 [2M+Na]+.
X-ray structural analysis
The single-crystal X-ray diffraction data of compound 6f
were collected on a diffractometer IPDS-2T (Stoe & Cie
GmbH, Darmstadt, Germany) at 180 K using Mo-Kα
radiation (l = 71.073 pm). The data reduction was per-
formed using the STOE X-AREA software package
(2006, Stoe & Cie, Darmstadt, Germany). The structure
was solved by direct methods using the program
SHELXS-97 and refined using SHELXL-97 [46]. All
non-H atoms were refined anisotropically, and hydrogen
(H) atoms were added geometrically using a riding
model. Graphical visualization of the structure was per-
formed using the program Diamond 3.2e (DIAMOND
3.2e, K. Brandenburg, 2010, Crystal Impact GbR, Bonn,
Germany). The crystal structure has been deposited at
the Cambridge Crystallographic Data Centre and allo-
cated the deposition number CCDC 841516.
Cell culture
CHO cell lines stably transfected with human CB1 (hCB1-
CHO; obtained from Euroscreen, Gosselies, Belgium) or
human CB2 (hCB2-CHO; obtained from Paul L. Prather,
Department of Pharmacology and Toxicology, College of
Medicine, University of Arkansas for Medical Sciences,
USA) were cultured in Ham's F12 medium or Dulbecco's
modified Eagle's medium (DMEM) with 10% fetal calf
serum, 100 IU/mL penicillin, 100 μg/mL streptomycin and
250 or 400 μg/mL of the selection antibiotic Geneticin
(G418), respectively. The cells were cultured in a humidi-
fied atmosphere with 5% CO2 at 37°C. Confluent cell layers
of 175-cm2 flasks were scraped; cells were harvested by
centrifugation (800 rpm, 3 min), counted by trypan blue
staining, suspended in 200 μL of 50 mM tris(hydroxy-
methyl)aminomethane (TRIS; pH 7.4) at 4°C and stored
at −32°C until the binding experiment.
Determination of CB receptor affinity
Competitive binding experiments were performed with
crude membrane homogenates obtained from hCB1-
CHO or hCB2-CHO cells as described above. Increasing
concentrations of test compounds (0.01 nM to 10 μM)
diluted from 10 mM stock solutions in DMSO wereincubated with 30 to 50 μg of membrane protein
(equivalent to 0.5 to 1 × 106 hCB1-CHO or hCB2-CHO
cells) and 0.5 nM [3H]CP55,940 (6,438 GBq/mmol;
PerkinElmer Life and Analytical Sciences, Rodgau,
Germany) in a final volume of 1 mL in a binding buffer
(50 mM TRIS (pH 7.4) at 21°C, 0.1% bovine serum al-
bumin (BSA), 5 mM MgCl2, 1 mM EDTA) for 90 min
at room temperature. Non-specific binding of [3H]
CP55,940 was determined in the presence of 10 μM
CP55,940. Incubations were terminated by rapid fil-
tration through a GF-B glass fibre filter pre-incubated
for 90 min at room temperature in freshly prepared
0.5% polyvinylpyrrolidone + 0.1% Tween 20 solution
using a 48-well cell harvester (Brandel, Gaithersburg,
MD, USA).
Saturation binding of CP55,940 towards hCB1-CHO
or hCB2-CHO cell membranes was analysed in homolo-
gous competition experiments performed with increas-
ing concentrations of CP55,940 (0.01 nM to 10 μM) and
one concentration of [3H]CP55,940 (0.5 nM). Kinetic
analysis of the binding of CP55,940 towards hCB2-CHO
cell membranes was performed in one association ex-
periment using three concentrations of [3H]CP55,940
(0.207, 0.458 and 0.873 nM) and incubation times of up
to 120 min.
Binding data were analysed using GraphPad Prism ver-
sion 2.01 (GraphPad Software, Inc., San Diego, CA,
USA) by non-linear regression to provide estimates of
the half maximal inhibitory concentration (IC50) values
and the rate of association. KD values of [
3H]CP55,940
from homologous radioligand displacement experiments
were estimated according to Jeffries et al. [47] by KD =
IC50 – [radioligand] and from kinetic experiments accord-
ing to Hulme and Trevethick [48]. The corresponding in-
hibition constants (Ki) of test compounds were derived
from the IC50 values using the Cheng-Prusoff equation
[49]. All binding experiments were performed in triplicates,
and data are given as mean values from independent
experiments.
Animals
Animal experiments were performed under procedures
approved by the State of Saxony Animal Care and Use
Committee and conducted in accordance with the
German Law for the Protection of Animals. Female
CD-1 mice (10 to 12 weeks old, 20 to 25 g), obtained
from the Medizinisch-Experimentelles Zentrum der
Universität Leipzig (Leipzig, Germany), were used for
the experiments.
Autoradiographic binding study
The animals were anesthetized and sacrificed, and their
spleens were rapidly removed and frozen in isopentane
at −35°C. The spleens were brought to −15°C in a
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Germany), and a series of 12-μm-thick coronal sections
obtained from the spleens of three animals were col-
lected in parallel on microscopic glass slides. The
sections were dried at room temperature and stored
at −35°C until they were processed for receptor binding
autoradiography.
For autoradiographic experiments, the slides were
brought to room temperature, dried in a stream of cold
air, pre-incubated in a binding buffer (50 mM TRIS (pH
7.4) at 21°C, 5% BSA) for 15 min at room temperature
and dried again in a stream of cold air. To account for
total binding, samples were incubated for 2 h at room
temperature with 6 nM [3H]CP55,940 (5,328 GBq/mmol,
PerkinElmer Life and Analytical Sciences, Rodgau,
Germany). Sections were incubated in the presence of
1 μM CP55,940 (non-specific binding), SR144528 (CB2-
selective inverse agonist), SR141716A (CB1-selective an-
tagonist), or a test compound in binding buffer. Samples
were washed twice for 30 min at 4°C in 50 mM TRIS
(pH 7.4) at 4°C, containing 1% BSA, dipped briefly in
ice-cold deionized water (5 s), dried in a stream of cold
air and exposed along with [3H] standards (Amersham/
GE Healthcare, Piscataway, NJ, USA) for 14 days to
[3H]-sensitive screen plates (Fuji Photo Film, Co. Ltd.,
Tokyo, Japan).
The image plates were analysed using a BAS-1800II
system bioimaging analyser (Fuji Photo Film, Co. Ltd.,
Tokyo, Japan). Scan data were visualized and processed
by computer-assisted microdensitometry (Aida version
2.31, Raytest Isotopenmessgeräte GmbH, Straubenhardt,
Germany). Irregular regions of interest (ROIs) were
drawn on selected areas of the spleen labelled as red
pulp (low-density binding) and white pulp (high-density
binding) according to Lynn and Herkenham [18] and
Massi et al. [39]. The intensity of the radioligand binding
was assessed by measuring the background-corrected
optical density in each ROI expressed as photostimu-
lated luminescence per square millimetre The theoretical
fractional occupancy (f ) of [3H]CP55,940 and the refer-
ence and test compounds at CB2 was calculated using
the Gaddum equation: fA = [A] / ([A] + KD,A(1 + [B]/
KD,B)) [50].
Receptor modelling
The receptor model was created employing the ‘Hom-
ology Modeling’ module of the program Molecular Op-
eration Environment (MOE, version 2010.11, Chemical
Computing Group Inc. Montreal, Canada). For this pur-
pose, the sequence of the human CB2 [Swiss-Prot:
P34972] [4] was subjected to a PDB search on the pro-
tein structure database implemented in MOE 2010.11
with the Z cut-off set to 2.0 while leaving the other para-
meters at their default values. The search suggested thehuman adenosine receptor A2a (hAA2R) as the template
for the comparative modelling procedure. Since the re-
cently published structure of the agonist-bound hAA2
receptor [43] is not included in the MOE protein data-
base, the hAA2R structure [PDB:3EML] [51] was chosen
as reference for the sequence alignment. The alignment
of the human CB2 sequence with that of hAA2R is given
as Additional files 1, 2, and 3. After downloading the 3D
structure of [PDB:3QAK] [43] from the RCSB database,
the structure was superimposed on the crystal structure
3eml. After removal of all lipid molecules, ions and
water molecules, the residues between 209 and 222,
which belong to lysozyme T4, were removed from the
structure. In order to improve the modelling accuracy,
the co-crystalized agonist UK-432097 of [PDB:3QAK]
remained in the system during the modelling procedure.
Out of ten independently generated models employing
the default parameters of the Homology Modeling mod-
ule, a consensus model was computed. To remove
clashes and optimize the overall geometry of the protein,
the system was subjected to an energy minimization
employing the implemented AMBER89 force field using
the default values. The quality of the model was verified
by running the Protein Report module of MOE. After
removal of the template ligand UK-432097, the apo re-
ceptor was energy-minimized to convergence, giving the
final hCB2 model structure.Docking studies
The small compounds were built in MOE with subse-
quent geometry optimization based on the MMFF force
field as incorporated in the program package with a
distance-dependent dielectric constant. The residues
of the proposed binding pocket were defined based on
the Site Finder module of MOE. The docking site
included residue Y1905.39 (numbering scheme accord-
ing to Ballesteros and Weinstein [52]), which is
known to be involved in ligand binding (cf. [53] and
references cited therein). For the molecular docking
studies, the program GOLD [54] (version 5) with
parameters set to their default values was employed.
All single bonds of the small ligands were allowed to
rotate freely during the docking simulation. The side
chains of the residues composing the binding pocket
were treated as flexible, and the atoms of the protein
backbone were kept at fixed positions. This approach
is considered to represent the main characteristics of
an induced fit [55]. The predicted poses were clus-
tered by the GOLD software with a cut-off of 1.0 Å
(heavy atoms only), giving representative geometries
of the small molecules. For each of the compounds,
all final poses were subjected to a further analysis
with the program PostDock [45].
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The radiolabelling procedure was initiated by addition of
K[18F]/K2.2.2 and K2CO3 to 2 mg of precursor in dry N,
N-dimethylformamide under diffuse light and argon at-
mosphere (6g: 293 MBq [18F]fluoride, K2.2.2 (7.4 μmol/
GBq) and K2CO3 (3.2 μmol/GBq); 6c: 303.2 MBq [
18F]
fluoride, K2.2.2 (7.4 μmol/GBq) and K2CO3 (3.2 μmol/
GBq)). The reaction mixtures were subjected to micro-
wave radiation in closed vessels employing a Discover
microwave synthesizer (CEM GmbH, Kamp-Lintfort,
Germany) with the following scheme: heating to 60°C
(30 s, 45 to 75 W with subsequent cooling to 20°C fol-
lowed by three radiation cycles (100°C (60 s, 150 W);
20°C). Subsequently, 5 eq. SnCl2 was added and the re-
action mixture was subjected to three heating cycles
(120°C (60 s, 150 W); 20°C). The yields of the labelled
compounds were determined by radio-TLC (EE/petrol
ether = 2:1).Conclusions
Various N-aryl-3-((hetero)aromatic)-oxadiazolyl-pro-
pionamides have been synthesized. Among those, 9-
ethyl-9H-carbazole-substituted compounds showed
the highest affinity towards CB2 and good selectivity
against CB1 receptors. The study revealed strong rela-
tionships between the structure of the CB2 ligands
and their CB2 affinity and selectivity. The data of this
study indicate that a modification of the compounds
at the amide moiety shows a stronger impact on bind-
ing and specificity of the compounds toward CB2 than
variation at the (hetero)aromatic ring located at the 3-
position of the oxadiazoles. Thus, introduction of
functional groups for subsequent 18F labelling at this
moiety is a promising strategy for the creation of CB2-
selective radioligands suitable for (neuro)imaging by
PET. Such imaging studies are currently in process at
our laboratory.Endnotes
aVendors of chemicals (details can be obtained from the
authors upon request): ABCR GmbH (Karlsruhe, Germany),
Activate Scientific GmbH (Prien, Germany), Alfa Aesar
Johnson Matthey Forschungschemikalien GmbH (Karlsruhe,
Germany), Apollo Scientific LTD (Cheshire, UK), Appli-
Chem GmbH (Darmstadt, Germany), Carl Roth GmbH &
Co. KG (Karlsruhe, Germany), Fisher Scientific GmbH
(Schwerte, Germany), Green Chempharm, Inc. (Bardonia,
NY, USA), Hande Sciences (Suzhou, China), Oakwood Pro-
ducts Inc. (West Columbia, SC, USA), Princeton BioMole-
cular Research (Munich, Germany), Sigma-Aldrich Chemie
GmbH (Munich, Germany), VWR International GmbH
(Darmstadt, Germany).Additional files
Additional file 1: Contains crystal data and structure refinement for
compound X-ray structural data of 6f. Crystal data: C26H20N6O4, Mm =
480.48 g mol–1, triclinic, space group P 1− (no. 2), a = 766.4(1) pm, b =
1236.3(1) pm, c = 1278.1(2) pm, α = 109.04(1)°, β = 100.34(1)°, γ = 91.31
(1)°, V = 1,121.8(2)·× 106 pm3, Z = 2, rcalc = 1.423 g cm
–3, μ(Mo-Kα) = 0.10
mm–1, crystal size 0.32 × 0.08 × 0.07 mm3, Qmax = 50°, 6,766 reflections
collected, 3,761 unique, Rint = 0.046, 2,382 observed reflections, 330
parameters, R1 = 0.043 [I > 2s(I)], wR2 = 0.082 (all data), maximum and
minimum residual electron density 0.18 and –0.14 × 10–6 Å–3,
respectively.
Additional file 2: Contains the alignment of the sequence of hCB2
with hAA2R.
Additional file 3: Contains the 3D coordinates of the modelled
human cannabinoid receptor 2.
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